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ABSTRACT 
Teriparatide is a bone anabolic treatment for osteoporosis, modeled in animals by intermittent 
PTH (iPTH) administration. iPTH-induced bone anabolism involves CD8+ T cell production of 
the osteogenic Wnt ligand Wnt10b, induced via yet unknown mechanisms. Here we show that 
Teriparatide and iPTH cause a ~2-3-fold increase in the number of regulatory T cells (Tregs) in 
humans and mice. Attesting in vivo relevance, blockade of the Treg increase in mice prevents 
iPTH-induced CD8+ T cell Wnt10b production and bone anabolism. Mechanistically, Treg action 
on CD8+ T cells promotes binding of NFAT1/2 and SMAD3 complexes to a NFAT/SMAD-
activated Wnt10b promoter region that stimualtes Wnt10b gene expression in CD8+ T cells. 
Therefore, increasing the number of Tregs is a pivotal mechanism by which iPTH exerts its 
bone anabolic activity. Increasing Tregs pharmacologically may represent a novel bone anabolic 
therapy, while iPTH-induced Treg increase may find applications in inflammatory conditions and 
transplant medicine. 
 
 
 
 
  
INTRODUCTION 
 
Primary hyperparathyroidism is a common cause of bone loss and fractures due to the 
continuous production of high levels of PTH by the parathyroid glands (Grey, Stapleton et al., 
1996, Potts, 1998). By contrast, when PTH is injected daily, a regimen known as intermittent 
PTH (iPTH) treatment, the hormone increases bone volume and strength due to a stimulation of 
bone formation tempered by a more moderate increase in resorption (Jilka, 2007, Uzawa, Hori 
et al., 1995).  As a result, intermittent treatment with the 1- 34 fragment of PTH is an FDA-
approved treatment modality for postmenopausal osteoporosis (Zaidi, 2007).   
PTH acts by binding to the PTH/PTHrP receptor PPR, which is expressed in all osteoblastic 
cells, including stromal cells (SCs), osteoblasts, and osteocytes (Calvi, Sims et al., 2001, 
Lanske, Amling et al., 1999, Powell, Barry et al., 2011, Rhee, Allen et al., 2011, Saini, Marengi 
et al., 2013).  Moreover, PPR is expressed in conventional CD4+ and CD8+ T cells (Terauchi, Li 
et al., 2009) and macrophages (Cho, Soki et al., 2014).  iPTH stimulates bone formation by 
increasing osteoblast formation and lifespan.  Activation of Wnt signaling in osteocytes and 
osteoblasts is one of the proposed mechanisms by which iPTH stimulates bone formation (Jilka, 
2007, Kramer, Loots et al., 2010, Qin, Raggatt et al., 2004). Wnt signaling activation is achieved 
through multiple mechanisms including Wnt ligand-independent activation of Wnt coreceptors 
(Wan, Yang et al., 2008), blunted osteocytic production of the Wnt inhibitor sclerostin (Bellido, 
Ali et al., 2005, Keller & Kneissel, 2005, Silvestrini, Ballanti et al., 2007) and decreased 
production by osteoblasts of the Wnt inhibitor Dkk1 (Guo, Liu et al., 2010).  
While osteocytes and their production of sclerostin are critical for the activity of iPTH, part of 
this hormone activity is sclerostin independent (Li, Walker et al., 2014) and mediated by T cells 
(Pacifici, 2013), a cell lineage that potentiates the anabolic activity of iPTH in trabecular bone 
(Bedi, Li et al., 2012, Li et al., 2014, Terauchi et al., 2009).  Accordingly, iPTH fails to stimulate 
bone formation and increase bone mass in T cell null mice (Terauchi et al., 2009).  By contrast, 
the effects of iPTH in cortical bone are completely T cell independent (Bedi et al., 2012, Li et al., 
2014, Terauchi et al., 2009), likely due to the fact that T cells have no contacts with periosteal 
surfaces and have limited capacity to communicate with osteocytes.  Among the T cells required 
for iPTH to exert its full anabolic activity are bone marrow (BM) CD8+ T cells (Terauchi et al., 
2009). CD8+ T cells express higher levels of the receptor PPR than CD4+ T cells (Bedi et al., 
2012, Li et al., 2014, Terauchi et al., 2009). Moreover, BM CD8+ T cells, but not CD4+ T cells, 
respond to iPTH by releasing Wnt10b (Bedi et al., 2012, Li et al., 2014, Terauchi et al., 2009), 
an osteogenic Wnt ligand that activates Wnt signaling in osteoblastic cells (Bennett, Ouyang et 
al., 2007).  Accordingly, silencing of Wnt10b production by CD8+ T cells blocks the capacity of 
iPTH to activate Wnt signaling in osteoblasts, stimulate bone formation and increase trabecular 
bone volume (Bedi et al., 2012, Li et al., 2014, Terauchi et al., 2009).  The relevance of Wnt10b 
has been confirmed in human studies demonstrating that treatment with Teriparatide, a form of 
iPTH treatment, increases the production of Wnt10b by peripheral blood T cells (D'Amelio, Sassi 
et al., 2015).  However, the mechanism by which iPTH regulates Wnt10b production remains to 
be determined.  
Regulatory T cells (Tregs) are a suppressive population of predominantly CD4+ T cells that 
play a critical role in maintaining immune tolerance and immune homeostasis. Tregs are 
comprised of thymus derived Tregs (tTregs, also known as nTregs) and peripherally derived 
Tregs (pTregs, also known as iTregs) (Abbas, Benoist et al., 2013).  Tregs are defined by the 
expression of the transcription factor Foxp3 and the ability to block inflammatory diseases and 
maintain immune homeostasis and tolerance (Shevach, 2009). Accordingly, defects in Treg 
numbers and/or activity have been implicated in several chronic inflammatory diseases. 
Moreover, Tregs have furthermore been found blunt bone resorption (Kim, Lee et al., 2007, 
Yuan, Li et al., 2010), prevent ovariectomy induced bone loss (Zaiss, Sarter et al., 2010), and 
regulate osteoclast formation (Kelchtermans, Geboes et al., 2009, Kim et al., 2007, Zaiss, 
Axmann et al., 2007). 
In vitro, conventional CD4+ T cells differentiate into Tregs by TCR stimulation under the 
influence of TGFb and IL-2 (Chen, Jin et al., 2003, Liu, Zhang et al., 2008, Ohkura, Kitagawa et 
al., 2013) .  Recently, IGF-1 has been recognized as an additional inducer of Tregs (Anguela, 
Tafuro et al., 2013, Johannesson, Sattler et al., 2014).  Since iPTH increases TGFb and IGF-1 
production in bone (Cho, Pirih et al., 2013, McCarthy, Centrella et al., 1989, Pfeilschifter, 
Laukhuf et al., 1995), it is likely that iPTH may induce and/or expand BM Tregs. 
This study was designed to investigate the effects of iPTH on Treg formation and activity in 
humans and mice, and to determine whether Tregs play a role in the bone anabolic activity of 
iPTH in mice. We report that treatment with iPTH increases the number of Tregs in humans and 
mice. In rodents, an increase in the number of Tregs is required for iPTH to exert its bone 
anabolic activity. We also show that in mice the increase in Tregs induced by iPTH activates 
NFAT1/2 and SMAD2/3 signaling in CD8+ T cells and blunts CD28 signaling in CD8+ T cells. 
These effects allow iPTH to upregulate the binding of NFAT/SMAD complexes to a site in the 
Wnt10b promoter critical for Wnt10b gene expression in CD8+ T cells.   Therefore, Tregs play a 
pivotal role in the production of Wnt10b and the resulting bone anabolic activity of iPTH.  
  
RESULTS  
 
Teriparatide treatment increases the number of Tregs in human peripheral blood  
 
The PTH fragment Teriparatide is the only approved bone anabolic treatment for osteoporosis 
but its intricate mechanism of action remains largely unknown. Among the pleiotropic effects of 
PTH, is the capacity to increase the production of TGFb1 and IGF-1 by human osteoblasts 
(Esen, Lee et al., 2015, Oursler, Cortese et al., 1991, Wu & Kumar, 2000), factors which induce 
Treg differentiation. To investigate whether Teriparatide regulates the number of Tregs in 
humans, 40 Italian women afflicted by postmenopausal osteoporosis of similar age and years 
since menopause were enrolled in a 6 month long prospective clinical trial. Twenty of the 40 
women were treated with calcium and vitamin D (control treatment), while the remaining 20 
women were treated with calcium, vitamin D, and human PTH 1-34 (Teriparatide), a treatment 
modality referred to hereafter as Teriparatide treatment. The baseline demographic 
characteristics of the study population and the serum levels of calcium, PTH and 25-hydroxy 
Vitamin D are shown in Table 1. Peripheral blood mononuclear cells (PBMC) were obtained at 
baseline, 3 and 6 months of treatment. Analysis by flow cytometry revealed that Teriparatide 
treatment increased the absolute and relative number of Tregs (CD4+CD25+Foxp3+ cells) in 
human PBMC at 3 and 6 months of treatment, compared to baseline (figure 1A,B).  By 
contrast, treatment with calcium and Vitamin D did not alter the number of Tregs during the 6 
months of the study.  As a result, both at 3 and 6 months the absolute and relative number of 
Tregs in PBMC was higher in women treated with Teriparatide than in those in the calcium and 
vitamin D control group.   
TGFb1 not only is a critical inducer of Treg differentiation, but is also an important product of 
Tregs that contributes to suppress effector T cells in vivo (Chaudhry & Rudensky, 2013, 
Shevach, 2009). Production of TGFb1 by Tregs is therefore an indicator of Treg function. To 
determine if Teriparatide regulates the function of Tregs, we measured the level of TGFb1 
mRNA in sorted peripheral blood CD4+CD25+ T cells from the last 18 women enrolled in the 
trial. We selected this cell population because most CD4+CD25+ T cells are Foxp3+ Tregs, 
while measurements of TGFb1 mRNA in Tregs sorted by Foxp3 staining is not feasible due to 
the loss of cell viability caused by intracellular staining. We found that the level of TGFb1 mRNA 
in this Treg enriched population was higher in the Teriparatide treated group than in the control 
group (figure 1C).  Post-hoc analysis showed that TGFb1 mRNA levels were higher at 3 
months than at baseline in the Teriparatide treated group. Moreover, at 6 months TGFb1 mRNA 
levels were higher in the Teriparatide treated group than in the control group. Together, these 
findings demonstrate that Teriparatide treatment expands the number and the activity of 
circulating human Tregs. 
To determine whether Teriparatide targets Tregs directly or indirectly, human peripheral blood 
CD4+CD25+ T cells were stimulated in vitro with CD3/CD28 Ab, IL-2 and TGFb at 2.5 ng/ml for 
6 days. Vehicle or Teriparatide (50 ng/ml) were added every 2 days for 1 or 24 hours. Analysis 
by flow cytometry revealed that Teriparatide did not increase the relative number of Tregs 
(CD4+CD25+Foxp3+ cells) in cultures of peripheral blood CD4+CD25+ T cells (figure 1D), 
suggesting that Teriparatide regulates the number of Tregs via indirect mechanisms. We also 
found that in vitro stimulation with Teriparatide does not increase the expression of TGFb mRNA 
in in sorted peripheral blood CD4+CD25+ T cells (figure 1E), confirming that Teriparatide does 
not directly targets Tregs. 
 
 
 
IPTH treatment in mice expands the pool of murine BM Tregs by increasing Treg 
differentiation 
 
As in human cells, in vitro PTH stimulation increases of production of TGFb1 and IGF-1 by 
murine osteoblasts (Cho et al., 2013, McCarthy et al., 1989, Pfeilschifter et al., 1995). However, 
the effects of iPTH treatment on the production of these factors is largely unknown.  To 
investigate this matter, 6 weeks old mice were treated with vehicle or iPTH for 2 weeks.  BM 
was then harvested and cultured for 24 hours. ELISA assays revealed that iPTH significantly 
increases the levels of TGFb1 and IGF-1 in the whole BM culture media (Supplemental figure 
1A,B), suggesting that iPTH may regulate Treg differentiation. 
To investigate the effect of iPTH treatment on the number of BM Tregs, 6-week-old mice were 
treated with vehicle or iPTH for 1, 2 or 4 weeks.  BM was then harvested and stained for TCRb, 
CD4 and Foxp3. iPTH treatment increased the relative and absolute number of BM Tregs 
(TCRb+CD4+Foxp3+ cells) during the entire study period (figure 2A,B). The increase in 
absolute number of BM Tregs was already significant at 1 week of iPTH treatment, peaked at 2 
weeks, and remained significantly increased at 4 weeks of treatment. 
iPTH could expand the pool of BM Tregs via multiple mechanisms including increasing the 
differentiation of conventional CD4+ T cells into Tregs or the proliferation of Tregs within the 
BM. To gain mechanistic insights, we determined the effects of iPTH on Treg differentiation, 
which is defined as the induction of Foxp3 expression in CD4+Foxp3- T cells (Shevach, 2009).  
For this purpose, we made use of B6.Foxp3.eGFP reporter mice, a strain in which eGFP 
expression is co-expressed with Foxp3 and restricted to CD4+ T cells.  Conventional CD4+ T 
cells (CD4+eGFP-) were FACS sorted from the spleens of B6.Foxp3.eGFP reporter mice and 
transferred into TCRb-/-mice, a strain lacking ab T cells.  After 2 weeks, a length of time 
sufficient for the engraftment and expansion of donor T cells, recipient mice were treated with 
vehicle or iPTH for 1-4 weeks.  We then determined the number of CD4+eGFP+ cells in the BM 
by flow cytometry. Treatment with iPTH increased the relative and the absolute number of 
CD4+eGFP+ cell in the BM at 1 week, 2 weeks, and 4 weeks of treatment (figure 2 C,D), 
demonstrating that iPTH increases the differentiation of BM Tregs.  Additional studies that used 
BrdU incorporation to measure proliferation, revealed that iPTH treatment for 1, 2 or 4 weeks 
does not increase BM Treg proliferation (Supplemental figure 2A).  Analysis of Treg 
differentiation in other organs revealed that iPTH treatment did not increase the differentiation of 
Tregs in the spleen (Supplemental figure 2B,C), thymus (Supplemental figure 2D,E), and 
intestinal lamina propria  (Supplemental figure 2F). In an additional set of experiments, Tregs 
(CD4+eGFP+ cells) were FACS sorted from the spleens of B6.Foxp3.eGFP reporter mice and 
transferred into TCRβ-/-mice. Recipient mice were treated with vehicle or iPTH for 2 weeks, 
starting the day of the Treg transfer. This design was selected to minimize the confounding 
effect of the partial loss of Foxp3 expression by CD4+eGFP+ cells, which may occur after Treg 
transfer into lymphopenic host mice (Duarte, Zelenay et al., 2009). These studies revealed that 
iPTH does not affect the relative and the absolute number of CD4+eGFP+ cells residing in the 
spleen and BM (Supplemental figure G-J).  These findings, together with a lack of an effect of 
iPTH on Treg proliferation, indicate that iPTH does not alter the homing of Tregs to the spleen 
and the BM.  
In addition to increasing the BM levels of TGFb and IGF-1 (Cho et al., 2013, McCarthy et al., 
1989, Pfeilschifter et al., 1995), iPTH enhances the sensitivity of conventional CD4+ cells to 
TGFb. This was disclosed by experiments in which unstimulated splenic CD4+CD25- cells 
purified from iPTH treated mice were found to express lower levels of the negative regulator of 
TGFβ signaling SMAD7 as compared to CD4+CD25- cells from vehicle treated mice 
(supplemental figure 3A). To ascertain the functional relevance of this finding, splenic 
CD4+CD25- cells from vehicle or iPTH treated mice were stimulated in vitro with CD3/CD28 Ab, 
IL-2 and TGFb at 2.5 ng/ml for 72 hours to induce their differentiation into Tregs (Karlsson, 
Robinson-Jackson et al., 2011). Measurements of phosphorylated SMAD2 and SMAD3 
(pSMAD2 and pSMAD3) at the end of the culture period revealed higher concentrations of 
pSMAD2 and pSMAD3 (supplemental figure 3B) in cells from iPTH treated mice as compared 
to those from control mice, suggesting that conventional CD4+ T cells from iPTH treated mice 
have a higher sensitivity to TGFb. To confirm this hypothesis, splenic CD4+CD25- cells were 
purified from vehicle or iPTH treated mice and then cultured in vitro for 72 hours with anti 
CD3/CD28 Ab, IL-2 and increasing doses of TGFb (0.1-5 ng/ml). At each dose of TGFb, 
cultures of CD4+CD25- T cells from iPTH treated mice yielded a greater percentage of Foxp3+ 
Tregs than those from vehicle treated mice (supplemental figure 3C). Together, these findings 
indicate that CD4+ T cells from iPTH treated mice possess a greater sensitivity to TGFb, which 
results in enhanced differentiation of CD4+ T cells into Tregs.  
 
An increase in the number of Tregs is required for iPTH to induce bone anabolism in 
mice 
 
A direct means to investigate the contribution of Tregs to the anabolic activity of iPTH is to 
assess the effects of iPTH in a model in which the increase in the frequency of Tregs is 
prevented.  The surface marker CD25 is expressed at high levels by most CD4+ Foxp3+ Tregs 
(Roncador, Brown et al., 2005). Accordingly, treatment with anti-CD25 Abs capable of deleting 
CD25hi is used to partially deplete Tregs in vivo (Setiady, Coccia et al., 2010, Tan, Reddy et al., 
2013).  We thus treated 6-week-old mice with vehicle or iPTH (days 1-28) plus 4 injections 
(days -2,0,5, and 7) of isotype control Ab or the anti-CD25 Ab PC61 (Setiady et al., 2010, Tan et 
al., 2013). We found CD25hi to be expressed by CD4+ T cells and by a negligible fraction of 
CD8+ T cells (supplemental figure 4A).  Anti-CD25 Ab decreased the frequency of CD25hi 
CD4+ T cells but not that of CD25lo CD4+ T cells.  As previously reported (Betts, Ho et al., 
2011), we also found that treatment with anti-CD25 Ab decreased the number of 
CD25hiFoxp3+CD4+ T cells, but not the number of CD25loFoxP3-CD4+ T cells (supplemental 
figure 4B). In addition, treatment with anti-CD25 Ab did not decrease the percentage of BM of 
conventional CD4+ T cells (TCRβ+CD4+CD25+Foxp3- cells) and that of CD8+ T cells 
(TCRβ+CD8+CD25+ cells) (supplemental figure 4C). Together, these findings demonstrate 
that anti-CD25 Ab specifically deplete Tregs. 
 At sacrifice control mice treated with anti-CD25 Ab had ~37 % fewer Tregs than mice treated 
with irrelevant (Irr.) Ab (figure 3A,B). Moreover, treatment with anti-CD25 Ab prevented the 
increase in BM Tregs induced by iPTH.  The partial depletion of Tregs induced by anti-CD25 Ab 
did not increase the production of inflammatory and lineage specific cytokines in the BM. In fact, 
in both the vehicle and iPTH treated groups, BM cells from mice treated with anti-CD25 Ab 
expressed similar levels of TNF, IL-17A, IL-6, IL-4 and IL-13 mRNAs to those from mice treated 
with Irr. Ab (Supplemental figure 5). Moreover, iPTH lowered the mRNA levels of IFNg, in both 
the Irr. Ab and the anti-CD25 Ab groups but did not affect the other cytokines. Since 
inflammatory cytokines blunt bone formation (Bertolini, Nedwin et al., 1986), these findings 
indicate treatment with anti CD25 Ab does not alter the bone anabolic activity of iPTH by 
inducing inflammation. Blockade of the increase in the number of Tregs by anti-CD25 Ab was 
associated with the loss of the capacity of iPTH to stimulate Wnt10b mRNA expression in T 
cells (figure 3C), a factor responsible for the bone anabolic activity of iPTH.  Analysis by in vitro 
µCT of femurs harvested at sacrifice revealed that iPTH induced a significant increase in 
trabecular bone volume (BV/TV) in mice treated with Irr. Ab (figure 3D,E), but not in those 
treated with anti-CD25 Ab. Trabecular thickness (Tb.Th), trabecular number (Tb.N), and 
trabecular space (Tb.Sp), which are indices of trabecular structure, were altered by iPTH in 
mice treated with Irr. Ab, but not in those treated with anti-CD25 Ab (Supplemental figure 6A-
C). By contrast, iPTH increase cortical volume (Ct.Vo) (figure 3D,F) and cortical thickness 
(Ct.Th) (Supplemental figure 6D) in both groups of mice, confirming that T cells are not 
implicated in the mechanism by which iPTH increases cortical volume.  Together, these findings 
demonstrate that the anabolic effects of iPTH in trabecular bone are dependent on increased 
numbers of Tregs.  
Analysis of femoral cancellous bone by histomorphometry revealed that iPTH increased the 
dynamic indices of bone formation mineral apposition rate (MAR) and bone formation rate 
(BFR/BS) in Treg replete mice but not in those treated with anti-CD25 Ab (figure 3G-I). 
Moreover, iPTH increased two static indices of bone formation, the number of osteoblasts per 
bone surface (N.Ob/BS) (figure 3J) and the percentage of surfaces covered by osteoblasts 
(Ob.S/BS) (figure 3K) in Treg replete mice but not in those treated with anti-CD25 Ab. The 
finding that treatment with anti-CD25 Ab did not decrease bone formation in vehicle treated 
mice provide evidence that partial Treg depletion does not cause a nonspecific inhibitory effect 
of on bone formation. Two indices of bone resorption, the number of OCs per bone surface 
(N.Oc/BS) and the percentage of surfaces covered by OCs (Oc.S/BS) were not affected by 
iPTH (figure 3L-N) in both control and Treg depleted groups. However, N.Oc/BS was higher in 
mice treated with iPTH and CD25 Ab, as compared to those treated with iPTH and Irr. Ab, 
suggesting that Treg depletion may stimulate bone resorption. 
Measurements of serum levels of osteocalcin, a marker for bone formation revealed that iPTH 
increased bone formation in mice treated with Irr. Ab but not in those treated with anti-CD25 Ab 
(figure 3O).  Serum CTX, a marker for bone resorption, also increased significantly in response 
to iPTH in mice treated with Irr. Ab but not in those injected with anti-CD25 Ab (figure 3P).  
Moreover, mice treated with anti-CD25 Ab had higher CTX levels than those treated with Irr. Ab, 
confirming that Treg depletion is associated with an increase in bone resorption.  The 
differences between the CTX data and histomorphometric indices of bone resorption are 
explained by the fact that CTX reflects cortical and trabecular bone resorption, while the 
histomorphometric analysis was limited to the trabecular compartment. 
To determine the role of Tregs in mediating the effects of iPTH on osteoblastogenesis, BM 
was harvested at sacrifice and cultured for 1 week to allow SCs to proliferate.  SCs were then 
purified and counted.  This analysis revealed that iPTH treatment increases the number of SCs 
in samples from mice treated with Irr. Ab while it had no effects in those treated with anti-CD25 
Ab (Supplemental figure 7A). To investigate the mechanism involved, BM was cultured for 1 
week, and SCs purified and used to determine their rate of proliferation and apoptosis.  These 
experiments revealed that iPTH increases significantly the proliferation of SCs from mice treated 
with Irr. Ab, while it had no effect on the proliferation of SCs from mice treated with anti-CD25 
Ab (Supplemental figure 7B).  iPTH decreased the rate of SC apoptosis in mice treated with 
Irr. Ab, while it had no effect on SC apoptosis in mice treated with anti-CD25 Ab (Supplemental 
figure 7C).  Analysis of the expression levels of osteoblastic genes in SCs revealed that iPTH 
treatment increased the expression of type 1 collagen, Runx2, Osterix, Bone Sialoprotein, and 
Osteocalcin mRNAs in SCs from mice treated with Irr. Ab, while it had no effect on SCs from 
mice treated with anti-CD25 Ab (Supplemental figure 7D). These findings demonstrate that 
iPTH regulates osteoblast proliferation, differentiation and life span through a Treg dependent 
mechanism. 
To further investigate the relevance of Tregs for the anabolic activity of iPTH, experiments 
were conducted utilizing DEREG mice (Lahl, Loddenkemper et al., 2007), a strain that 
expresses a fusion protein of the human diphtheria toxin (DT) receptor (hDTR) and eGFP under 
control of the Foxp3 promoter.  Foxp3+ Tregs can be selectively depleted upon DT 
administration to DEREG mice, since WT mice do not express the hDTR receptor and are thus 
insensitive to DT.  DT is known not to cause toxic effects in mice (Klingenberg, Gerdes et al., 
2013). While Treg ablation in DEREG mice causes scurfy-like symptoms in newborn animals, 
older mice do not develop autoimmune diseases (Klingenberg et al., 2013, Lahl et al., 2007) as 
DT treatment of older DEREG mice causes a partial Treg depletion (Lahl & Sparwasser, 2011) 
and the residual Treg population is sufficient to prevent disease in adult mice (Lahl & 
Sparwasser, 2011).  We treated 6-week-old mice with DT (1 µg/mouse, i.p. 2 times per week for 
4 weeks), a treatment modality titrated to block the increase in Tregs induced by iPTH. Mice 
were also treated with vehicle or iPTH for 4 weeks starting after the first two DT injections. 
Controls included DEREG mice not treated with DT and WT littermate (LM) mice treated with 
DT.  Analysis of BM samples harvested at sacrifice revealed that iPTH had expanded Tregs in 
control mice but not in DEREG +DT mice (figure. 4A,B).  As expected, analysis of vehicle 
treated groups showed that DEREG + DT mice had a lower absolute and relative numbers of 
Tregs as compared to control groups. Analysis of BM T cells harvested at sacrifice revealed that 
iPTH did not increase Wnt10b mRNA expression in DEREG + DT mice, while it caused 
significant increases in Wnt10b mRNA levels in the two control groups (figure 4C). Analysis by 
µCT of femurs harvested at sacrifice revealed that iPTH induced a significant increase in BV/TV 
in the two control groups but not in DT treated DEREG mice (figure 4D,E).  Analysis of distal 
femurs also revealed that Tb.Th, Tb.N, and Tb.Sp were differentially altered by IPTH in Treg 
replete and Treg depleted mice (Supplemental figure 6E-G).  By contrast, iPTH increased 
Ct.Vo (figure 4D,F) and cortical thickness (Ct.Th) (Supplemental figure 6H) in all groups of 
mice. Together, these findings confirmed that the anabolic effects of iPTH in trabecular bone are 
dependent on increased numbers of Tregs.  
Analysis of femoral cancellous bone by histomorphometry revealed that iPTH increased the 
dynamic indices of bone formation MAR and BFR/BS in the two control groups but not in DT 
treated DEREG mice (figure 4G-I). N.Ob/BS and Ob.S/BS, which are static indices of bone 
formation, were also increased by iPTH in DEREG mice and littermate controls but not in 
DEREG + DT mice (figure 4J,K). Two indices of bone resorption, N.Oc/BS and Oc.S/BS were 
similar in all groups of mice (figure 4L-N). Analysis of biochemical markers of bone turnover 
revealed that iPTH increased serum level of osteocalcin and CTX in control mice but not on 
Treg depleted mice (figure 4O,P), confirming that the increase in the number of BM Treg is 
required for iPTH to increase bone turnover.  In vehicle treated mice, serum CTX was higher in 
Treg depleted mice that in Treg replete controls, confirming that Treg depletion leads to a 
stimulation of bone resorption. 
 
Tregs increase the production of Wnt10b induced by iPTH in mice by blunting CD28 
signaling and inducing NFAT and SMAD signaling in CD8+ T cells. 
 
Previous reports have demonstrated that CD8+ T cell produced Wnt10b is critical for the 
anabolic activity of iPTH in the trabecular compartment of the skeleton (Bedi et al., 2012, Li et 
al., 2014, Terauchi et al., 2009). The current investigation has revealed that stimulation of CD8+ 
T cell production of Wnt10b by iPTH is mediated by Tregs. An important issue that remains to 
be addressed is whether Tregs per se contribute to the increase in the BM levels of Wnt10b 
induced by iPTH.  Studies conducted in sorted populations of BM T cells from B6.Foxp3.eGFP 
reporter mice revealed that iPTH does not increase the expression of Wnt10b mRNA by 
conventional CD4+ T cells (TCRb+CD4+eGFP- cells) and Tregs (TCRb+CD4+ eGFP + cells) 
(figure 5A). These findings confirm earlier reports from our laboratory  (Bedi et al., 2012, Li et 
al., 2014, Terauchi et al., 2009) and argue against a direct contributory role of Tregs to the pool 
of BM Wnt10b of iPTH treated mice.  
Another pivotal issue is the mechanism by which Tregs regulate the capacity of iPTH to 
increase Wnt10b production by CD8+ T cells. The NFAT family of transcription factors includes 
5 members, NFAT1 to 5, of which NFAT1 (NFATc2) and NFAT2 (NFATc1) play a central role in 
peripheral CD4+ and CD8+ T cell activation, tolerance, anergy and exhaustion (Fehr, Lucas et 
al., 2010, Heissmeyer, Macian et al., 2004, Macian, Garcia-Cozar et al., 2002). Activation of 
calcineurin upon TCR signaling leads to dephosphorylation of NFATs, which then translocate to 
the nucleus where they activate transcription by interacting with AP-1 or other nuclear proteins 
including SMADs (Macian, 2005).  The Wnt10b promoter possesses 3 DNA monomeric core 
binding motifs for NFATs, located in close proximity to binding sites for the TGFb signaling 
proteins SMADs.  This arrangement suggest that iPTH-induced Wnt10b transcription might be 
regulated by the binding of NFAT/SMAD dimers to the Wnt10b promoter. This hypothesis is 
further supported by reports that PTH and PTHrP activate NFAT signaling in osteoblasts 
(Huang, Chikazu et al., 2010, Park, Baek et al., 2015), by the fact that PTH increases the 
production of TGFb by osteoblasts (Pfeilschifter et al., 1995), and by data presented herein 
indicating that iPTH increases the BM levels of TGFb1 protein (Supplemental figure 1). 
To investigate the relevance of SMADs and NFATs for Wnt10b gene expression, we first 
measured Wnt10b mRNA levels in purified splenic CD8+ T cells after in vitro stimulation with the 
SMAD inducer TGFb and the NFAT activator ionomycin. We found that stimulation with both 
TGFb and ionomycin markedly increased Wnt10b production while TGFb or ionomycin alone 
had a significant, yet less potent, effect (figure 5B), indicating a potential role of SMAD and 
NFAT signaling in Wnt10b gene expression.  
To determine if NFATs and SMADs bind to the Wnt10b promoter, ChIP assays were 
conducted in BM CD8+ T cells from vehicle and iPTH treated mice. We found that CD8+ T cells 
from iPTH treated mice had higher binding of NFAT1, NFAT2, and SMAD3 (but not SMAD2) to 
the Wnt10b promoter as compared to CD8+ T cells from vehicle treated mice (figure 5C).  
Blockade of the increase in the number of Tregs by in vivo treatment with anti-CD25 Ab 
prevented iPTH from increasing the binding of NFAT1, NFAT2, and SMAD3 to the Wnt10b 
promoter, thus demonstrating that Tregs are required for iPTH to increase the binding of these 
transcription factors to the Wnt10b promoter. 
To investigate the functional relevance of NFAT/SMAD binding to the Wnt10b promoter we 
cloned a 2,000 bp upstream region of the mouse Wnt10b gene containing the three putative 
NFAT/SMAD binding sites into a luciferase reporter plasmid. The Wnt10b-luc reporter plasmid 
(or empty vector) together with TK-pRL transfection control vector were transfected into primary 
murine CD8+ T cells or EL4 cells. After transfection, cells were rested for 24 hours and then 
stimulated with ionomycin and TGFb for 24 hours to activate Wnt10b transcription. Cell lysates 
were then assessed by dual luciferase assay kit, as an index of promoter activity. We found that 
stimulation with ionomycin and TGFb increased Wnt10b promoter activity (figure 5D). Deletion 
of the 2 most distal NFAT/SMAD binding sites did not alter the activity of the reporter.  By 
contrast, deletion of all 3 NFAT/SMAD binding sites abolished the activity of the reporter, 
suggesting that the NFAT/SMAD binding site critical for Wnt10b transcription is located between 
-705 bp and -272 bp in the Wnt10b promoter.  Site directed mutagenesis experiments confirmed 
(figure 5E) that the critical binding site is located between -705 bp and -272 bp in the Wnt10b 
promoter. Mutation of both the SMAD and the NFAT sites lowered the activity of the reporter in 
in primary murine CD8+ T cells and EL4 cells to baseline levels.  Mutation of the NFAT binding 
site alone also decreased the activity of the reporter to baseline levels, while mutation of the 
SMAD site alone resulted in a marked decrease, but not a complete inhibition, of the reporter 
activity. 
Having demonstrated that iPTH increases the binding of NFATs and SMADs to the Wnt10b 
promoter, we next investigated how iPTH and Tregs regulate NFAT and SMAD signaling in 
CD8+ T cells. We found that iPTH increases the translocation of pSMAD2, pSMAD3, NFAT1 
and NFAT2 into the nucleus of BM CD8+ T cells (figure 6A). Blockade of Treg numeric 
increase by treatment with anti-CD25 Ab prevented the iPTH-induced nuclear translocation of 
pSMAD2, pSMAD3, NFAT1 and NFAT2 (figure 6A), confirming that Tregs play a pivotal role in 
activating NFAT and SMAD signaling in CD8+ T cells.  
While NFAT signaling is known to be activated by PPR signaling (Huang et al., 2010), 
SMAD2/3 signaling is induced by TGFb. PTH increases the osteoblastic production of TGFb, 
but it is possible that PTH might also increase TGFb production by Tregs. Tregs express LAP-
associated TGFb (LAP+ TGFb) and secrete TGFb (Schmidt, Oberle et al., 2012, Shevach, 
2009).  Analysis by flow cytometry revealed that iPTH increases the relative and absolute 
number of LAP+ Tregs (TCRb+CD4+Foxp3+LAP+ cells) (figure 6B,C). As expected, treatment 
with anti-CD25 Ab markedly lowered the number of LAP+ Tregs and prevented the increase in 
LAP+ Tregs induced by iPTH (figure 6B,C). Treatment with anti-CD25 Ab also prevented iPTH 
from upregulating the production of TGFb1 protein levels by CD4+ cells (figure 6D). Studies 
using FACS sorted BM Tregs from vehicle and iPTH treated Foxp3.eGFP reporter mice, 
established that iPTH treatment increases TGFb1 mRNA levels in Tregs (CD4+eGFP+ cells) 
(figure 6E). Expression of TGFb1 mRNA by purified BM cells populations is shown in figure 6F.  
Together, these data demonstrate that a consequence of the numeric increase in BM Tregs 
induced by iPTH is an increase in the amount of TGFb available for upregulating nuclear 
pSMAD levels in CD8+ T cells. While iPTH increases the differentiation of naïve CD4+ cells into 
TGFb-expressing Tregs, iPTH did not increase the Treg expression of IL-10, IL-12 and Ebi3, the 
two subunits of IL-35 (Supplemental figure 8). 
To determine whether Treg-produced TGFb is sufficient to activate SMAD signaling in CD8+ T 
cells, OVA specific CD8+ T cells were purified from the spleen of OT-I mice and cocultured with 
OVA peptide pulsed CD11c+ DCs with and without Tregs for 2 hours. Analysis of pSMAD2 and 
pSMAD3 in CD8+ T cells by western blotting revealed that the addition of Tregs to the 
cocultures resulted in increased translocation of pSMAD2 and pSMAD3 to the nucleus of CD8+ 
T cells (figure 6G). By contrast, Tregs did not upregulated the translocation of NFAT1 and 
NFAT2, confirming that the activation of NFAT signaling is not induced directly by Tregs.  
NFAT and AP-1 form high affinity complexes binding to composite DNA sites present in genes 
critical for T cell activation and effector cytokine production (Fehr et al., 2010, Heissmeyer et al., 
2004, Macian et al., 2002). In activated T cells, which express AP-1 at high levels, AP-1 acts as 
the preferred partner of NFAT. Blockade of CD28 costimulation by Tregs, lowers the production 
of AP-1, forcing NFAT to bind to other partners such as SMADs (Macian, 2005). In accordance 
with this notion, we found that Tregs lowered c-Fos and c-Jun translocation in antigen activated 
CD8+ T cells (figure 6G). Moreover, we found that in vivo iPTH treatment did not increase the 
nuclear levels of c-Fos and c-Jun in CD8+ T cells (figure 6H), while it increased the levels of 
NFAT1/2 and pSMADS2/3 (figure 6A).  These findings are relevant as they suggest that iPTH 
treatment favors the association of NFAT with SMADs.  
Next, we investigated the role of Tregs in the production of Wnt10b induced by PTH and the 
involved mechanisms. OT-I CD8+ T cells were cocultured with OVA peptide pulsed CD11c+ 
DCs with and without Tregs for 24 hours. Some groups were also stimulated with PTH for the 
last 4 hours of incubation. CD8+ T cells were then purified and assayed for Wnt10b mRNA 
expression. In these conditions, which closely mimic the behavior of Tregs in vivo, CD8+ T cells 
from cocultures containing Tregs expressed ~ 3-fold higher Wnt10b mRNA levels than those 
without Tregs (figure 6I), indicating that Tregs increase the baseline production of Wnt10b. 
Stimulation with PTH did not increase CD8+ T cell production of Wnt10b in the absence of 
Tregs. By contrast, PTH increased CD8+ T cell expression of Wnt10b mRNA by ~6-fold in the 
presence of Tregs, demonstrating that Tregs are required for PTH to induce Wnt10b production 
by CD8+ T cells.   
Tregs suppress conventional T cell activation via several mechanisms (Shevach, 2009).  One 
of most relevant is inhibition of CD28 signaling in conventional T cells (Wing, Onishi et al., 
2008).  To investigate the role of CD28 signaling, OT-I CD8+ T cells were cocultured for 24 
hours with OVA peptide pulsed CD11c+ DCs and with and without CTLA-4-Ig, an inhibitor of 
CD28 costimulation (Najafian & Sayegh, 2000). Some groups were also stimulated with PTH for 
the last 30 minutes or the last 4 hours. Confirming that blockade of CD28 costimulation by Tregs 
lowers the production of AP-1, we found that CTLA-4Ig lowered c-Fos and c-Jun translocation in 
antigen activated CD8+ T cells (figure 6J). CTLA-4Ig without PTH downregulated the 
translocation of NFAT1, NFAT2 in fully activated cells, a finding consistent with the stimulatory 
role of CD28 signaling in T cell activation.  However, the activation of NFAT1 and NFAT2 was 
increased by combined treatment with CTLA-4Ig and PTH (figure 6K), confirming the capacity 
of PTH to activate NFAT signaling. Importantly, CTLA-4Ig with and without PTH did not affect 
the translocation of pSMAD2 and pSMAD3.  In these conditions neither CTLA-4-Ig alone nor 
PTH alone increased Wnt10b mRNA production by CD8+ T cells (figure 6K). However, 
stimulation with both CTLA-4Ig and PTH resulted in a ~7-fold increase in Wnt10b mRNA levels, 
demonstrating that blunting of CD28 signaling increases the capacity of PTH to stimulate 
Wnt10b production.  
To further demonstrate the relevance of CD28 signaling for PTH-induced transcription of 
Wnt10b, we again transfected the Wnt10b-luc reporter plasmid (or empty vector) together with 
TK-pRL transfection control vector into primary CD8+ T cells. We found that stimulation with 
anti-CD3 Ab with and without anti-CD28 Ab increased Wnt10b promoter activity above baseline 
levels (figure 6L). In vitro PTH treatment further increased Wnt10b promoter activity, but only in 
CD8+ T cells stimulated by anti-CD3 Ab without anti-CD28 Ab. This finding provides additional 
support to the hypothesis that T cell receptor (TCR) activation in the absence of CD28 signaling 
increases the responsiveness of the Wnt10b gene to PTH.  Moreover, in this experiment the 
NFAT inhibitor 11R-VIVIT blocked the increase in promoter activity induced by PTH, a finding 
demonstrating that PTH induced Wnt10b promoter activity is NFAT dependent (figure 6L).  
Inhibition of CD28 signaling is a key mechanism by which Tregs repress conventional T cells 
(Wing et al., 2008).  Moreover, inhibition of CD28 signaling favors the association of NFATs with 
SMADs by decreasing nuclear levels of AP-1. Therefore, a final set of experiments was 
designed to confirm that iPTH blunts CD28 signaling in CD8+ T cells and investigate the 
involved mechanism. We found that iPTH downregulated the level of phosphorylated PI3K 
(figure 7A) and pAKT in BM CD8+ T cells (figure 7B,C), which are kinases downstream of 
CD28. These effects of iPTH were prevented by treatment with anti-CD25 Ab, confirming that 
the increase in the number of Tregs induced by iPTH blunts CD28 signaling in CD8+ T cells. An 
established mechanism by which Tregs blunt CD28 signaling in conventional T cells is the 
downregulation of the expression of the CD28 ligands CD80/86 (B71/B72) by DCs (Shevach, 
2009). Attesting to the involvement of this mechanism, we found that iPTH decreased the 
relative and absolute number of CD80+ mature DCs (CD11c+MHC-II+CD40+CD80+ cells) 
(figure 7D,E) and the relative and absolute number of CD86+mature DCs (CD11c+MHC-
II+CD40+CD86+ cells) (figure 7 F,G).  
 
  
DISCUSSION 
 
iPTH treatment is an approved bone anabolic treatment for osteoporosis but its intricate 
mechanism of action remains largely unknown.  We report (figure 8) that in vivo iPTH treatment 
increases the number of BM Tregs in mice. The increase of the BM Treg pool is essential for the 
bone anabolic activity of iPTH. The increase in the number of Tregs is due to enhanced 
differentiation of peripherally induced Tregs, a phenomenon driven by the capacity of iPTH to 
upregulate the levels of TGFb and IGF-1 in the BM and to increase the sensitivity of naïve CD4+ 
cells to TGFb. The numeric increase in Tregs lessens CD28 signaling in conventional BM CD8+ 
T cells. Stimulation of CD8+ T cells by iPTH in conditions of blunted CD28 signaling results in 
the binding of NFAT1/2 and SMAD3 proteins to the Wnt10b promoter and activation of Wnt10b 
gene expression. This Wnt ligand is required for iPTH to induce trabecular bone anabolism 
(Bedi et al., 2012, Li et al., 2014, Terauchi et al., 2009).  To translate our findings in humans, we 
measured the absolute and relative frequency of Tregs in the peripheral blood of osteoporotic 
women treated with Teriparatide, a form of iPTH treatment.  We found that Teriparatide 
increases the number of Tregs at 3 and 6 months of treatment.  Teriparatide also increases 
TGFb1 mRNA levels, an indicator of Treg activity. By, contrast, we found that in vitro treatment 
of Tregs with PTH does not affect the number of Tregs and TGFb production, indicating that 
iPTH regulates human Tregs indirectly. 
Tregs are a suppressive population of predominantly CD4+ T cells that play a critical role in 
maintaining immune tolerance and immune homeostasis. Accordingly, defects in Treg numbers 
and/or activity have been implicated in several chronic inflammatory diseases. Tregs are also 
know to regulate osteoclast formation (Kelchtermans et al., 2009, Kim et al., 2007, Zaiss et al., 
2007), blunt bone resorption (Kim et al., 2007, Yuan et al., 2010), and prevent ovariectomy 
induced bone loss (Zaiss et al., 2010). However, CD4+Foxp3+ Tregs have not been previously 
reported to stimulate bone formation, and iPTH treatment was not known to regulate the number 
of BM Tregs. 
Our findings demonstrate that one mechanism by which iPTH expands murine BM Tregs is 
enhanced differentiation of peripherally induced Tregs. We also found iPTH not to alter Treg 
proliferation and homing to the BM. Whether additional mechanisms, such as increased life-
span contribute to the numeric increase of BM Tregs remains to be determined.  
PPR is expressed by conventional CD4+ cells and CD8+ cells but not by Tregs.  On the other 
hand, iPTH upregulates the BM levels of TGFb and IGF-1, factor capable of inducing Treg 
differentiation in vitro (Anguela et al., 2013, Chen et al., 2003, Johannesson et al., 2014, Liu et 
al., 2008, Ohkura et al., 2013).  Therefore, iPTH is likely to induce murine Treg differentiation 
indirectly.   
In the mouse, iPTH treatment for 4 weeks did not increase the number of Tregs in the spleen, 
thymus and intestinal wall, suggesting that a treatment period longer than 4 weeks might be 
required for iPTH to expand Tregs in peripheral blood and lymphoid organs, a hypothesis 
supported by our findings in humans at 3 and 6 months of treatment. It is also likely that the 
increase in Tregs induced by iPTH occurs first in the BM because of environmental cues. iPTH 
increases the osteoblastic production of TGFb and the bone matrix is the largest reservoir of 
TGFb in the body (Koh, Novince et al., 2011, Pfeilschifter et al., 1995). iPTH also increases the 
osteoblastic production of IGF-1 (McCarthy et al., 1989, Pfeilschifter et al., 1995).  It is thus 
likely that in the first 4 weeks of treatment the increase in the number of Tregs induced by iPTH 
is confined to the BM because of the higher levels of TGFb and IGF-1 present in the BM as 
compared to the spleen. 
We have used two experimental models to assess the relevance of Tregs for the anabolic 
activity of iPTH in the mouse, depletion of Tregs in WT mice by treatment with anti-CD25 Ab, 
and depletion of Tregs in DEREG mice by treatment with DT. Both strategies prevented the 
increase in the number of Tregs induced by iPTH. In both cases, blockade of the increase in the 
number of Tregs prevented the increases in bone formation and trabecular bone volume 
induced by iPTH, demonstrating that an enlargement of the pool of BM Tregs is required for 
iPTH to increase trabecular bone mass.  Blockade of the increase in the number of Tregs also 
prevented the increase in Wnt10b production induced by iPTH. This Wnt ligand is required for 
iPTH to induce bone anabolism (Bedi et al., 2012, Li et al., 2014, Terauchi et al., 2009). 
Accordingly, blockade of Tregs and silencing of Wnt10b production by CD8+ T cells (Bedi et al., 
2012, Terauchi et al., 2009) equally blunt the anabolic activity of iPTH in trabecular bone.  By 
contrast, blockade of Tregs did not blunt the capacity of iPTH to increase cortical bone volume.  
These findings are in agreement with previous reports from our laboratory demonstrating that T 
cells and Wnt10b do not contribute to iPTH-induced cortical bone anabolism (Bedi et al., 2012, 
Li et al., 2014, Terauchi et al., 2009). We hypothesize that iPTH induces cortical bone 
anabolism primarily by regulating the osteocytic production of sclerostin. 
The Wnt10b promoter possesses 3 DNA monomeric core motifs for NFAT binding in close 
proximity to SMAD binding sites. We found one of these binding sites, located between -705 bp 
and -272 bp in the Wnt10b promoter, to be critical for the Wnt10b transcription induced by IPTH. 
The NFAT family of transcription factors includes 5 members, NFAT1 to 5, of which NFAT1 
(NFATc2) and NFAT2 (NFATc1) play a central role in CD4+ and CD8+ T cell activation, 
tolerance, anergy and exhaustion (Fehr et al., 2010, Heissmeyer et al., 2004, Macian et al., 
2002). Activation of calcineurin upon TCR signaling leads to dephosphorylation of NFATs, which 
then translocate to the nucleus where they activate transcription by interacting with AP-1 and 
other nuclear proteins (Macian, 2005). We found that iPTH treatment upregulates the nuclear 
translocation of NFAT1/2 and SMAD2/3 and the binding of NFAT1/2 and SMAD3 to the Wnt10b 
promoter in BM CD8+ T cells. As previously reported for other promoters (Dichlberger, Schlager 
et al., 2014, Tone, Furuuchi et al., 2008), SMAD2 did not cooperate with NFAT to induce 
Wnt10b expression.  
 Tregs express high levels of membrane-bound and soluble TGFβ (25, 57). We found iPTH 
treatment to increase the expression of membrane bound TGFb by Tregs and partial Treg 
depletion by treatment with anti-CD25 Ab to block the increase the nuclear levels of SMAD2 and 
SMAD3 induced by iPTH. It is thus likely that increased expression of membrane bound TGFb 
by Tregs provides iPTH with a mechanism to activate SMAD signaling in CD8+ T cells in close 
proximity to Tregs. Tregs are highly mobile cells, therefore even a relative low number of TGFb+ 
Tregs may activate SMAD signaling in many CD8+ cells.  Moreover, it appears likely that PTH 
induces NFAT translocation by directly targeting CD8+ T cells, as PTH and PTHrP have been 
previously shown to directly activate NFAT signaling in other cell lineages (Huang et al., 2010, 
Park et al., 2015). Importantly, since blockade of Tregs dampens the translocation of NFAT to 
the nucleus of CD8+ T cells, NFAT activation by iPTH requires signals conveyed to CD8+ T 
cells by an enlarged population of Tregs. However, we cannot conclusively exclude the 
possibility that iPTH activates NFAT signaling in CD8+ T cells via a non-cell autonomous effect 
mediated by Tregs. 
Tregs suppress conventional T cell activation through a multitude of mechanisms (Shevach, 
2009), including the blunting of CD28 signaling in CD8+ T cells (Wing et al., 2008). Accordingly, 
we found that iPTH lessen CD80/CD86 expression on antigen presenting cells, thereby 
reducing CD28 signaling in conventional BM CD8+ T cells. CD28 signaling is relevant for 
regulating the association of NFAT to its partners because it leads to the activation of AP-1, 
which is the preferred partner of NFAT (Fehr et al., 2010, Heissmeyer et al., 2004, Macian et al., 
2002). As a result, in the context of T cell activation, NFAT and AP-1 form high affinity 
complexes binding to composite DNA sites present in genes critical for T cell activation and 
effector cytokine production (Fehr et al., 2010, Heissmeyer et al., 2004, Macian et al., 2002). 
Blockade of CD28 costimulation by Tregs, lowers the production of AP-1, favoring the binding of 
NFAT to other partners, such as SMADs (Macian, 2005).   
In this study, we found evidence in support of the relevance of CD28 signaling blockade for 
the increase in Wnt10b gene expression induced by iPTH. This evidence includes in vitro 
studies demonstrating that antibody-induced activation of CD28 blocks the capacity of PTH to 
activate Wnt10b gene expression. Conversely, blockade of CD28 signaling in vitro by CTLA-4Ig 
results in higher production of Wnt10b. Attesting to the relevance of repression of CD28 
signaling for Wnt10b production in vivo, we have reported that in vivo inhibition of CD28 
signaling via treatment with CTLA-4Ig increases expression of Wnt10b by CD8+ T cells and 
bone mass in a manner similar to iPTH (Roser-Page, Vikulina et al., 2014).  Therefore, iPTH 
favors the formation of lower affinity complexes between NFAT1/2 and SMAD3, which bind to 
the Wnt10b promoter and stimulation of Wnt10 transcription.  
Recently, there has been an explosion in research investigating the potential to manipulate 
Tregs for clinical purposes (Brunstein, Miller et al., 2011, Di Ianni, Falzetti et al., 2011, Feng, Hu 
et al., 2013, Marek-Trzonkowska, Mysliwiec et al., 2012, Trzonkowski, Bieniaszewska et al., 
2009). Among these studies are several phase I clinical trials to test whether boosting Treg 
numbers and/or function is a feasible, safe, and potentially effective way to treat diseases such 
as graft vs. host disease, type 1 diabetes and to prevent the rejection of transplanted organs 
(Brunstein et al., 2011, Di Ianni et al., 2011, Feng et al., 2013, Marek-Trzonkowska et al., 2012, 
Trzonkowski et al., 2009).  Osteoporosis is a common chronic disorder that represents a major 
source of disability in the elderly. Novel anabolic treatments are needed because the long-term 
use of current antiresorptive agents is associated with significant adverse events and 
complications.  An increase in the number of Treg is achievable by Treg transfer or treatment 
with mTOR inhibitors, self-antigens or cytokines (von Boehmer & Daniel, 2013), and inhibition of 
CD28 costimulation (e.g. CTLA-4Ig).  Based on our findings, pharmacological Tregs may 
represent a novel therapeutic modality for osteoporosis or for potentiating the anabolic activity of 
iPTH. Moreover, the use of iPTH to increase the number of Tregs may find applications in 
transplant medicine or as a treatment for inflammatory and autoimmune conditions. 
AUTHOR CONTRIBUTIONS: MY, RDP, MNW, and RP designed the animal studies. PDA, 
FS and IB designed and performed the human studies and analyzed the human data. MY, CV, 
AMT, JYL, EH, JA and MS performed the research and analyzed the animal data. RP wrote the 
manuscript.  
 
ACKNOWLEDGEMENTS 
This study was supported by grants from the National Institutes of Health (RP:DK108842, 
AR54625, and RR028009; JYL: AR061453; MNW: AG040013, AR068157 and AR070091). 
MNW was also supported by a grant from the Biomedical Laboratory Research & Development 
Service of the VA Office of Research and Development (5I01BX000105).  
  
MATERIAL AND METHODS 
 
Human Study population.  All human studies were approved by the Ethical Committee of the 
A.O.U. Città della Salute e della Scienza - A.O. Ordine Mauriziano - A.S.L. TO1, Turin Italy and 
informed consent was obtained from all participants.  The study population was recruited from 
the patients of A.O.U. Città della Salute e della Scienza, Turin Italy.  The study population 
included 34 women affected by postmenopausal osteoporosis (PMO). The demographic 
characteristics of the study population are shown in table 1. The diagnosis of PMO was 
established based on WHO criteria (1984) the presence of secondary osteoporosis was ruled 
out by medical history, physic examination and blood exams quantifying calcium, phosphorus, 
25OH vitamin D and PTH. Inclusion and exclusion criteria are provided in supplemental 
experimental procedures. Seventeen patients were treated with calcium carbonate (1000 
mg/day) and colecalcipherol 800 UI/day (control treatment). The remaining seventeen patients 
were treated with human PTH 1-34 (Teriparatide, Eli Lilli, Indianapolis) 20 μg/day 
subcutaneously, calcium carbonate (1000 mg/day) and colecalcipherol 800 UI/day. Patients in 
the Teriparatide group had prior fragility fractures, whereas those in the control treatment group 
had not, according to guide lines for PMO treatment of the Italian Health ministry. Blood 
samples (40 ml) were collected in EDTA containing vacuum tubes at baseline and after 3 and 6 
months of treatment.  Exclusion criteria are provided in supplemental information. 
Study design.  No randomization procedure was used to assign humans and mice to 
experimental groups.  All murine and human samples were analyzed in blinded fashion. The 
Investigators analyzing the human samples were blind to the identity of the study participant, 
disease state, treatment status and all other clinical variables. The Investigators analyzing 
mouse samples were blind the genotype and treatment group. Congenic WT mice or non-
transgenic littermates were used as controls for transgenic mice.  
 
Inclusion and eexclusion criteria for the human study population.   
None of the subjects enrolled were affected by disease states affecting bone health other than 
PMO. Subjects affected by renal or hepatic insufficiency or chronic inflammatory conditions 
such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease were excluded, as 
these diseases are known to influence bone status. Subjects treated with drugs active on bone 
turnover such as bisphosphonates, denosumab, teriparatide, hormone replacement therapy, 
selective estrogen receptor modulator, strontium ranelate, glucocorticoids, androgens or GN-RH 
agonists for any length of time during the 6 months prior to enrolment were excluded. 
Flow cytometric analysis of human samples. Peripheral blood mononuclear cells (PBMCs) 
were purified from 40 ml peripheral blood obtained from all patients at each time point using the 
Ficoll–Paque gradient method, as previously described (D'Amelio, Grimaldi et al., 2005). The 
Human Regulatory T-cell Staining Kit (eBioscience Inc. San Diego, CA, USA) was used in 
accordance with manufacturer’s instructions to stain PBMC for Tregs. Briefly, the following 
labelled monoclonal antibodies and corresponding isotype controls were used: anti-CD4 (FITC-
conjugated); anti-CD25 (APC-conjugated); and anti-Foxp3 (PE-conjugated). After surface 
staining for CD4 and CD25, cells were washed, fixed and permeabilized (Fix-Perm Buffer). Cells 
were then incubated with anti-Foxp3 for intra-nuclear staining. Flow cytometry was performed 
on an Accuri C6 flow cytometer (BD Biosciences). 
Human T cells immunomagnetic separation. Human CD4+CD25+ T cells were isolated 
from whole blood at each time point using The Complete Kit for Human CD4+CD25+ Regulatory 
T Cells which includes RosetteSep CD4+ T Cell Enrichment Cocktail and EasySep Human 
CD25 Positive Selection Kit (STEMCELL Technologies) according to the manufacturer 
instructions. The purity of CD4+CD25+ T cells was 93-95 % as assessed by flow cytometry. 
Real-time RT-PCR and human primers.  RT-PCR was used to evaluate the mRNA levels of 
TGFβ1 in CD4+CD25+ T cells. RNA was isolated using TRIzol reagent (Ambion, Huntingdon, 
UK), according to the manufacturer’s protocol. 1 µg of RNA was reverse transcribed to single-
stranded cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied-Biosystems). 
RT-PCR was performed with IQ SYBR Green Supermix (BIORAD). The housekeeping control 
gene was β-Actin and gene expression was quantified using the 2-∆∆Ct method.  The primers 
used were as follows: 5'-CTCTCCGACCTGCCACAGA-3' (forward) and 3'-
TCTCAGTATCCCACGGAAATAACC-5' (reverse) for TGFβ1; 5’- 
CCTAAAAGCCACCCCACTTCT -3' (forward) and 3’- CACCTCCCCTGTGTGGACTT -5' 
(reverse) for β-Actin.   
In vitro PTH treatment of human CD4+CD25+ T cells.  Purified CD4+CD25+ T cells were 
cultured for 6 days in RPMI medium containing 10% fetal bovine serum (FBS), 1% Penicillin 
Streptomycin (Gibco, Thermo Fisher Scientific, MA, USA), 500U/ml rIL-2 (Tebu-bio srl, Milano, 
ITALY) and 2 μg/ml anti-CD3 antibody (Biolegend, San Diego, CA, USA)  and cultured for 16h 
in the absence of PTH 1-34. Human PTH 1-34 (50 ng/ml) or control vehicle was added to the 
cultures for 1 hour or 24 hours for 3 times during the 6-days culture to mimic the anabolic effects 
of intermittent PTH 1-34. Cells were then harvested and utilized for flow cytometry and RNA 
extraction. 
Animals.   All the animal procedures were approved by the Institutional Animal Care and Use 
Committee of Emory University. All in vivo experiments were carried out in female mice. In vitro 
experiments were conducted using primary cells from female mice or EL4 cells. Female 
C57BL/6 WT, TCRβ-/-, DEREG and Foxp3 eGFP knock-in mice were purchased from Jackson 
Laboratories (Bar Harbor, ME).  All mice were maintained under specific pathogen free 
conditions and fed sterilized food (5V5R chow) and autoclaved water ad libitum. 
In vivo iPTH treatment.  For the in vivo iPTH studies, 80 µg/kg/day of hPTH 1-34 (Bachem 
California Inc., Torrance, CA) or vehicle was injected daily subcutaneously into female mice for 
1-4 weeks starting at the age of 6 weeks, as described (Bedi et al., 2012, Li, Adams et al., 2012, 
Li et al., 2014, Terauchi et al., 2009).   
  T cell purification and adoptive transfer. Splenic T cells from 6-8 weeks old Foxp3 eGFP 
knock in mice were enriched by negative selection using EasySep Mouse T Cell Isolation Kit 
(StemCell Technologies, Auburn, CA). Next, conventional CD4+ T cells (CD4+eGFP-) were 
purified from enriched splenic T cells by FACS sorting and transferred into 4 weeks old TCRβ-/- 
recipient mice by IV injection (3 × 106 cells per mouse). Recipient mice were treated with vehicle 
or iPTH for 1-4 weeks starting 2 weeks after the CD4+eGFP- cell transfer. For Treg isolation, 
CD4+eGFP+ cells were sorted from enriched splenic T cells of Foxp3 eGFP knock in mice and 
injected into 6 weeks old TCRβ-/- recipient mice via tail vein (2 × 106 cells per mouse). The 
purity of CD4+eGFP+ cells was 99 % checked by flow cytometry. Vehicle or iPTH treatment 
were started the day of the Treg transfer for 2 weeks. At the end of the treatment period, the 
number of CD4+eGFP+ cells was determined by flow cytometry in spleen and BM cells. 
Small intestine Lamina propria lymphocyte (SILP) isolation.  Lamina propria lymphocyte 
isolation was performed as described (Li, Chassaing et al., 2016). Briefly, the small intestine 
was removed and flushed of fecal contents, and intestinal segments containing Peyer’s patches 
were excised.  The intestine was opened longitudinally and cut into 5 mm pieces. Tissues were 
transferred into a 50 ml conical tube, and shaken at 250 rpm for 20 min at 37°C in HBSS 
medium (Life Technologies, Grand Island, NY) supplemented with 5% FBS (Mediatech Inc., 
Manassas, VA) containing 2 mM EDTA. This process was repeated two additional times. The 
tissue suspension was passed through a strainer, and the remaining intestinal tissue was 
washed and then minced, transferred into a fresh 50 ml conical tube, and shaken for 20 min at 
37°C in HBSS + 5% FBS containing type VIII collagenase (Sigma-Aldrich, St. Louis, MO) at 1.5 
mg/ml. The tissue suspension was collected, passed through a strainer, and pelleted by 
centrifugation at 1200 rpm for 3 min. The pellet was suspended in 10 ml HBSS medium and 
passed through glass wool halfway packed in a 10 ml syringe to remove undigested tissue 
pieces. The cell suspension was collected in a 50 ml tube and centrifuged at 1200 rpm for 3 
min. The pellet was suspended in 5 ml HBSS and 5 ml 90% isotonic Percoll, and then 
transferred into a 15 ml tube and mixed by tilting back and forth. The cell content was layered 
onto 2 ml of 70% isotonic Percoll. The gradient was centrifuged at 2000 rpm for 20 min. Cells 
were collected from the interface area and washed by centrifugation in 10 ml supplemented 
RPMI-1640 medium supplemented with 5% FBS. The cell pellet was resuspended in 10 ml 
supplemented RPMI-1640 and cell number was counted.   
Anti-CD25 Ab treatment.  6-week-old WT mice were injected daily with vehicle or PTH for 4 
weeks (day 1 to 28). Mice were also injected with anti-CD25 Ab (clone PC61, 500 
µg/mouse/injection IP) (BioXCell, West Lebanon, NH) on days -2, 0, 5 and 7 or isotype matched 
irrelevant Ab.  
DT treatment. DT was purchased from Merck (catalog number 322326), and each lot was 
tested for toxicity in WT mice and titrated for potency in DEREG mice prior to use. DEREG and 
littermate control mice were administered 1 µg DT intraperitoneally on two consecutive days 
each week for total four weeks.   
µCT measurements.  μCT scanning and analysis of the distal femur was performed as 
reported previously (Li, D'Amelio et al., 2015, Li et al., 2014, Robinson, Li et al., 2015) using a 
Scanco µCT-40 scanner (Scanco Medical, Bassersdorf, Switzerland).  
Femoral trabecular and cortical bone regions were evaluated using isotropic 12-μm voxels.  
For the femoral trabecular region we analyzed 140 slices from the 50 slices under the distal 
growth plate. Femoral cortical bone was assessed using 80 continuous CT slides located at the 
femoral midshaft.  X-ray tube potential was 70 kVp, and integration time was 200ms.   
Quantitative bone histomorphometry.  The measurements, terminology and units used for 
histomorphometric analysis, were those recommended by the Nomenclature Committee of the 
American Society of Bone and Mineral Research (Dempster, Compston et al., 2013).  Non-
consecutive longitudinal sections of the femur were prepared and analyzed as described 
previously (Li et al., 2015). Mice were injected subcutaneously with calcein at day 7 and day 2 
before sacrifice. Non-consecutive longitudinal sections (5 µm thick) were cut from methyl 
methacrylate plastic-embedded blocks along the frontal plane using a Leica RM2155 microtome 
and were stained with Goldner’s trichrome stain for the static measurements.  Additional 
sections were cut at 10 μm, and left unstained for dynamic (fluorescent) measurements. 
Measurements were obtained in an area of cancellous bone that measured ≈ 2.5 mm2 and 
contained only secondary spongiosa, which was located 0.5–2.5 mm proximal to the epiphyseal 
growth cartilage of the femurs.  Measurements of single-labeled and double-labeled fluorescent 
surfaces, and interlabel width were made in the same region of interest using unstained 
sections. Mineral Apposition Rate (MAR) and Bone Formation Rate (BFR) were calculated by 
the software by applying the interlabel period.  Histomorphometry was done using the Bioquant 
Image Analysis System (R&M Biometrics). 
Markers of bone turnover.  Serum CTX and osteocalcin were measured by rodent specific 
ELISA assays (Immunodiagnostic Systems, Scottsdale, AZ).  
Stromal cells purification. BM SCs were purified as previously described (Bedi et al., 2012, 
Li et al., 2014, Terauchi et al., 2009). In brief, BM cells from long bones were cultured for 7 days 
in α-MEM medium containing 10% FBS, 100 mg/mL of penicillin, and 100 IU/mL of 
streptomycin, to allow the proliferation of SCs. After removing non adherent cells, adherent 
macrophages were eliminated by positive immunoselection using anti-CD11c MACS 
Microbeads (Miltenyi Biotech, Auburn, CA, USA). The remaining adherent cells were defined as 
SCs as they express alkaline phosphatase (ALP), type-I collagen, and Runx2, and have the 
capacity to form mineralization nodules when further cultured under mineralizing conditions. 
BrdU incorporation studies.  Mice were injected IP with 40 mg/kg/day of BrdU solution for 
four days and sacrificed 24 hours later.  BrdU detection was performed by using the BrdU Flow 
Kit (BD Biosciences, San Diego, CA) and analyzing cells by flow cytometry.  The percentage of 
BrdU+ Treg cells was quantified by gating CD4+Foxp3+ cells in the TCRβ+ cell population. 
SC Thymidine incorporation assay. The proliferation of purified SCs was measured by [3H]-
thymidine incorporation assay. SCs were pulsed with [3H]-thymidine (0.5 μCi/10,000 cells) for 
18 hours, and were harvested with a Cell Harvestor (Skatron, Inc., Sterling, VA, USA). [3H]-
thymidine incorporation was read by a LS 6000 IC Liquid Scintillation Counter (Beckman 
Coulter, Inc., Fullerton, CA, USA). 
SC apoptosis assay. The activity of caspase-3, the critical protease in the induction of 
apoptosis, was measured in SCs using CaspACE Assay System (Promega Corporation, 
Madison, WI, USA) according to the manufacturer's protocol. 
In vitro Treg differentiation. Assessment of Treg differentiation in vitro was carried out as 
described (Fantini, Dominitzki et al., 2007). Splenic CD4+ T cells from WT mice treated with 
vehicle or iPTH were purified by negative selection using EasySep Mouse CD4+ T Cell Isolation 
Kit (StemCell Technologies, Auburn, CA). CD25+ cells were then removed using the EasySep 
Mouse CD25 Regulatory T Cell Positive Isolation Kit (StemCell Technologies, Auburn, CA). The 
remaining cells (CD25- enriched CD4+ T cells) were cultured in plates coated with anti-CD3 Ab 
(3 µg/ml) in the presence of anti-CD28 Ab (3 µg/ml), IL-2 (5 ng/ml), and TGFβ1 (0.1-5 ng/ml) for 
3 days. Cells were then harvested and analyzed by flow cytometry to enumerate CD4+Foxp3+ 
cells. 
In vitro generation of induced Tregs. The generation was carried out as described 
(Karlsson et al., 2011) . Briefly, purified splenic CD4+CD25- T cells from WT mice at the 
concentration of one million each ml completed RPMI-1640 medium were cultured in plates 
coated with anti-CD3 Ab (10 µg/ml) in the presence of recombinant human IL-2 (100 U/ml), 
TGFβ1 (20 ng/ml) and all trans retinoic acid (1 pmol/ml) for 4 days. The conversion ratio of cells 
reached 95 % (the percentage of Foxp3+ cells in total CD4+ population). 
Flow cytometry. Flow cytometry was performed on a LSR II system (BD Biosciences, 
Franklin Lakes, NJ) and data were analyzed using FlowJo software (Tree Star, Inc., Ashland, 
OR). For intracellular Foxp3 staining, APC-Foxp3 (eBioscience) antibody was added after cell 
fixation and permeabilization with BD Transcription Factor Buffer Set (BD Biosciences). For 
phospho-epitope analysis, resting total BM cells were fixed with BD Cytofix Fixation Buffer for 
10 min at 37°C, permeabilized in BD Phosflow Perm Buffer III for 30 min on ice, and stained 
with PE anti-AKT (pS473) (BD Biosciences). The antibodies used for cell surface staining are 
provided as supplemental information. The following anti-mouse antibodies were used for cell 
surface staining:  purified CD16/32, BV 421-TCRβ, PerCP/Cy5.5-CD4, PE-CD25, BV 711-CD8, 
FITC-B220, APC/Cy7-CD3, PerCP/Cy5.5-F4/80, BV 421-CD11c, Alexa Fluor 700-I-A/I-E, PE-
CD40, APC-CD80, PE-LAP(Biolegend, San Diego, CA) and BV650-CD86 (BD Biosciences).  
Real-time RT-PCR and murine primers.  WT BM CD8+ T cells were enriched using 
EasySep Mouse CD8a positive Selection Kit II (StemCell Technologies, Auburn, CA) while WT 
spleen CD8+ T cells were purified by negative selection with EasySep Mouse CD8+ T Cell 
Isolation Kit (StemCell Technologies, Auburn, CA). BM TCRβ+CD4+eGFP- , 
TCRβ+CD4+eGFP+ (Treg) and TCRβ+CD8+ T cells from Foxp3 eGFP knock in mice were 
FACS sorted by FACS ARIA II.  Total RNA was isolated from WT cells including total BM cells, 
splenic CD8+ T cells or BM CD8+ T cells using TRIzol reagent (ThermoFisher Scientific). FACS 
Sorted cells were lysed using the Cells-to-cDNA II Kit (ThermoFisher Scientific). For all RNA 
samples, cDNA was synthesized with random hexamer primers (Roche) and AMV reverse 
transcriptase (Roche).  mRNAs levels of murine Wnt10b and TGFβ1 in T cells, that of bone 
sialoprotein (BSP), collagen 1 (CoL1), osteocalcin (Ocn), osterix (Osx) and runt-related 
transcription factor 2 (Runx2) in SCs and that of TNF, IL-6, IFNγ, IL-4, IL-13 and IL-17A in total 
BM were quantified by real-time PCR.  .  Changes in relative gene expression between vehicle 
and iPTH groups were calculated using the 2–DDCT method with normalization to 18S rRNA. The 
primers used are provided in supplemental Table 1. 
TGF-β1 and IGF-1 ELISA BM cells from long bones were cultured for 24 hr. Supernatants 
were collected and assayed for TGF-β1 or IGF-1 by ELISA kits (R&D Systems) following the 
manufacturer’s instruction. When checking TGF-β1, the medium without the cells was run as the 
control of the baseline levels of TGF-β1. To isolate CD4+ T cells from BM, BM CD8+ T cells 
were discarded by EasySep Mouse CD8a positive Selection Kit II (StemCell Technologies). 
CD4+ T cells were then positively isolated using APC-anti-TCRβ antibody and EasySep Mouse 
APC Positive Selection Kit (StemCell Technologies).  
Western Blotting. The nuclear and cytoplasmic fractionations of fresh BM CD8+ T cells were 
obtained using NE-PER Nuclear and Cytoplasmic Extraction Reagents (ThermoFisher 
Scientific). Halt Protease and Phosphatase Inhibitor Cocktail (ThermoFisher Scientific) were 
added into the reagents before using. Lysates were cleared by centrifugation and the 
supernatants were boiled in SDS loading buffer. The same amount of proteins was separated 
on 10% Mini-PROTEAN TGX Precast Gels (Bio-rad) and electroblotted to nitrocellulose 
membrane (ThermoFisher Scientific). Proteins were detected by anti-NFAT1, anti-c-Jun 
(ThermoFisher Scientific), anti-NFAT2, anti-c-Fos (Santa Cruz Biotechnology), anti-phospho-
Smad2 (Ser465/467) or anti-phospho-Smad3 (Ser423/425) antibody (Cell Signaling 
Technology, Danvers, MA)/anti-Smad3 (phosphor S423+ S425) (Abcam). Anti-beta Tubulin 
(Abcam) and anti-Lamin B1 (Cell Signaling Technology, Danvers, MA) antibodies were used to 
confirm the purity of subcellular fractionations, respectively. Anti-beta actin antibody was bought 
from Santa Cruz Biotechnology and used as the loading control for the testing of Smad7 (Santa 
Cruz Biotechnology), phospho-Smad2 (Ser465/467) and phospho-Smad3 (Ser423/425) (Cell 
Signaling Technology, Danvers, MA) in the whole lysate from splenic conventional CD4+ T cells 
or phospho-PI3K p85 (Cell Signaling Technology, Danvers, MA) in the whole lysate from BM 
CD8+ T cells. Western blot analysis was conducted by using Luminata Crescendo Western 
HRP substrate (EMD Millipore). Band intensities were quantified with Quantity One 1D Analysis 
Software (Bio-Rad Laboratories) and expressed relative to Lamin B1 or beta-actin. 
Plasmids and site-directed mutagenesis. The plasmid containing -2000 to +216 bp DNA 
sequence of mouse Wnt10b promoter was constructed by inserting a PCR product of mouse 
genomic DNA into the pGL3.0 vector (Promega, Madison, WI). mWnt10b-luc (-705 to +216 bp) 
is a gift from Dr. D. J. Klemm, University of Colorado, Denver. Other shortened constructs were 
subcloned basing on the construct of mWnt10b-luc (-2000 bp to +216 bp).  The amplification 
template for all mutations is the mWnt10b-luc (-705 to +216 bp). The NFAT binding site (5’-
AGGAAAA-3’) at -282 to -276 bp was changed to 5’-AGcttAA-3’ using the Q5 Site-Directed 
Mutagenesis Kit (New England BioLabs). Similarly, the SMAD binding site (5’-GTCTAGA-3’) at -
341 to -335 bp was mutated to 5’-catagcg-3’. The primers used are provided in supplemental 
Table 1. 
Wnt10b promoter reporter gene assays. EL4 cell line bought from ATCC (ATCC number: 
TIB-39 and lot number: 61840715). EL4 cells were negative for mycoplasma contamination 
according to the Hoechst DNA method and agar culture method. The cells were transfected with 
either 1.8 µg pGL3 basic vector or 1.8 µg mWnt10b-luc reporter construct together with 0.2 µg 
TK-pRL control vector using the Amaxa Nucleofector system and Amaxa Cell Line Nucleofector 
Kit L (Lonza).  For primary cells, freshly purified spleen CD8+ T cells were transfected with 
either 3.6 µg pGL3 basic vector or 3.6 µg mWnt10b-luc reporter construct together with 0.4 µg 
TK-pRL control vector using the Amaxa Nucleofector system and Amaxa Mouse T Cell 
Nucleofector Kit (Lonza). Cells were left unstimulating for 24 h and cultured with ionomycin (0.5 
µg/ml, Sigma) plus TGFβ1 (5 ng/ml, Biolegend) for another 24 h. In some experiments, 
unstimulated, anti-CD3 Ab or anti-CD3/CD28 Ab stimulated cells were transfected with 
constructs separately. Transfected cells were left unstimulated for 24 h or treated with 4 µM 
11R-VIVIT (Merck Millipore) and/or 50 nM PTH(1-34) after 22 h for the last 2 h. Luciferase 
activity was determined by the Dual-Luciferase reporter assay kit (Promega BioSciences, San 
Luis Obispo, CA). 
ChIPs. Chromatin immunoprecipitation (ChIP) assays were performed using Pierce Agarose 
ChIP Kit (ThermoFisher Scientific) and following the detailed manufacturer’s instructions. Fresh 
purified BM CD8+ T cells were fixed in 1% formaldehyde for 10 minutes. Chromatin was 
digested by micrococcal nuclease to an average length of 200-1000 bp. The similar amounts of 
chromatin were immunoprecipitated with 2 µg of anti-NFAT1 (MA1-025, ThermoFisher 
Scientific), anti-NFAT2 (7A6, Santa Cruz Biotechnology), anti-Smad3 (ChIP grade, Abcam), 
anti-Smad2 (Cell Signaling Technology, Danvers, MA) or control rabbit IgG. Isolated DNAs were 
quantitated using ABI SYBR Green PCR master mix (Applied Biosystems) on an ABI 
StepOnePlus Real-Time PCR System and calculated as fold enrichment compared with 
background signal. The primers used are provided in Supplemental Table 1. 
APC assay and in vitro CTLA-4Ig treatment. The assay was performed as previously 
described (Roser-Page et al., 2014). Additional information is provided as supplemental 
information. Splenic CD11c+ dendritic cells (DCs) sorted by immunomagnetic beads (Miltenyi 
Biotech) were used as antigen presenting cells. CD8+ T cells expressing a monoclonal 
ovalbumin (OVA)-specific transgenic TCR were purified from the spleens of OT-I mice by 
negative selection.  CD11c+ DCs were pulsed for 4 hours with 1 µM antigen (OVA peptide) 
(SIINFEKL, InvivoGen). After two time washes with medium, cells were ready for APC assay. 
For induced Treg coculture, OVA presenting dendritic cells at 150,000/well were incubated with 
splenic OT-I CD8+ T cells (1 million/well) with or without induced Tregs (1million/well) for 24 h 
and with or without hPTH 1-34 (100nM) (Bachem California Inc., Torrance, CA) at last 4 h. 
CD8+ T cells were separated by positive selection beads and dissolved in TRIzol reagent for 
RNA isolation and Wnt10b mRNA level assay by real time RT-PCR. For western blotting, the 
time of coculture of OVA presenting dendritic cells, CD8+ T cells and induced Tregs was 2 h. 
During CTLA-4-Ig treatment, OVA presenting dendritic cells at 150,000/well were incubated with 
splenic OT-I CD8+ T cells (1 million/well) with or without CTLA-4-Ig (100 µg/ml) for 24 h. The 
treated times of PTH at final time point are 4 h for real time PCR and thirty minutes for western 
blotting	
Statistical Analysis. Human Tregs and human TGFb1 data were analyzed by ANOVA for 
repeated measures. Human demographic and clinical data were analyzed by unpaired two 
tailed t-tests. When murine data were normally distributed according to the Shapiro-Wilk 
normality test they were analyzed by unpaired two tailed t-tests, one-way or two-way analysis-
of-variance, as appropriate. This analysis included the main effects for animal strain and 
treatment plus the statistical interaction between animal strain and treatment.  When the 
statistical interaction between animal strain and treatment group was not statistically significant 
(p > 0.05) nor suggestive of an important interaction (p > 0.10), p values for the main effects 
tests were reported. When the statistical interaction was statistically significant (p < 0.05) or 
suggestive of an important interaction, then t tests were used to compare the differences 
between the treatment means for each animal strain, applying the Bonferroni correction for 
multiple comparisons. Data that were not normally distributed (as tested by Shapiro-Wilk 
normality test) were analyzed by Kruskal-Wallis non-parametric tests. 
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Table 1. Demographic and clinical data of patients with postmenopausal osteoporosis treated 
with calcium and vitamin D, or calcium and vitamin D and Teriparatide. Data are shown as 
Mean + SEM, p values were calculated by unpaired t-test.  Values in squared parenthesis 
denote normal range.  
 Control Teriparatide p 
n 20 20 
 
Age 68.5 ± 1.8 69.7 ± 1.6 0.535 
Years since menopause 
18.4 ± 2.1 20.8 ± 1.6 0.232  
Ca (mg/dL) 
[8.8-10.4 mg/dl] 
9.6 ± 0.1 9.5 ± 0.1 0.851 
Serum P (mg/dL) 
[2.5-4.48 mg/dl] 
 
3.5 ± 0.2 
 
3.4 ± 0.1 
 
0.608 
PTH (pg/mL) 
[10-65 pg/mL] 
 
42.8 ± 9.3 
 
46.8 ± 4.1 
 
0.272 
25OH vitamin D (ng/mL) 
[20-100 ng/mL] 
 
30.2 ± 3.1 
 
27.3 ± 2.7 
 
0.997 
 
 
 
 
 
 
 
  
 FIGURE LEGEND  
 
Figure 1.  Teriparatide treatment in humans increases the absolute and relative number of 
Tregs in peripheral blood and TGFb expression by Tregs. A.  Relative frequency of Tregs in 
PBMC at 3 and 6 months of treatment. n = 17 patients per group. B. Absolute frequency of 
Tregs in PBMC at 3 and 6 months of treatment.  n = 20 patients per group. C. mRNA levels of 
TGFb1 in peripheral blood CD4+CD25+ T cells at 3 and 6 months of treatment.  n = 9 patients 
per group. D. Relative frequency of Tregs in cultures of in peripheral blood CD4+CD25+ T cells 
stimulated with vehicle or PTH. E. mRNA levels of TGFb1 in peripheral blood CD4+CD25+ T 
cells stimulated with vehicle or PTH. All data are expressed as Mean + SEM. All data were 
normally distributed according to the Shapiro-Wilk normality test and analyzed by 2-way ANOVA 
for repeated measures. *= p<0.05, **= p<0.01, and ***= p<0.001 compared to baseline. # = 
p<0.05, and ## = p<0.01, compared to Ca + D group. 
 
Figure 2. iPTH treatment increases the number of BM Tregs and Treg differentiation. To 
determine the effect of treatment on the number of Tregs, BM TCRb+CD4+Foxp3+ T cells were 
counted by flow cytometry following 1, 2 and 4 weeks of treatment with vehicle or iPTH.  To 
assess Treg differentiation, conventional CD4+ T cells (TCRb+CD4+eGFP-) from 
B6.Foxp3.eGFP reporter mice were transferred into TCRb-/-mice. Recipient mice were treated 
with vehicle or iPTH for 1,2 or 4 weeks starting 2 weeks after the T cell transfer. The number of 
BM TCRb+CD4+eGFP+ cells was then determined by flow cytometry.  A.  Relative frequency of 
BM Tregs at 1, 2 and 4 weeks of treatment. n = 10-32 mice per group. B. Absolute frequency of 
Tregs at 1, 2, and 4 weeks of treatment.  n = 10-32 mice per group. C.  Relative frequency of 
eGFP+ Tregs at 1, 2, and 4 weeks of treatment n = 10 mice per group. D. Absolute frequency of 
eGFP+ Tregs at 1, 2, and 4 weeks of treatment n = 10 mice per group. Data are expressed as 
Mean + SEM. All data were normally distributed according to the Shapiro-Wilk normality test 
and analyzed by unpaired T tests. ***= p<0.001, and ****= p<0.0001 compared to the 
corresponding vehicle. 
Figure 3. Depletion of Tregs by treatment with anti-CD25 Ab prevents the bone anabolic activity 
of iPTH. A,B. Relative and absolute frequency of BM Tregs. C. Wnt10b mRNA levels in BM 
CD8+ T cells. D. Images of representative 3-dimensional µCT reconstructions of examined 
femurs from each group E. Femoral trabecular bone volume (BV/TV) as measured by µCT 
scanning. F. Femoral cortical bone volume (Ct.Vo) by µCT scanning G. Images are 
representative sections displaying the calcein double-fluorescence labeling. Original 
magnification x 20. H. Mineral apposition rate (MAR), I. Bone formation rate per mm bone 
surface (BFR/BS). J. The number of osteoblasts per mm bone surface (N.Ob/BS). K. The 
percentage of bone surface covered by osteoblasts (Ob.S/BS).  L. The images show tartrate 
resistant acid phosphatase (TRAP) stained sections of the distal femur.  Original magnification x 
40. M. The number of osteoclasts per mm bone surface (N.Oc/BS).  N. The percentage of bone 
surface covered by osteoclasts (Oc.S/BS). O. Serum levels of osteocalcin (OCN), a marker of 
bone formation. P. Serum levels of type 1 cross-linked C-telopeptide (CTX), a marker of 
resorption. n=10-25 mice per group.  Data are expressed as Mean + SEM. All data were 
normally distributed according to the Shapiro-Wilk normality test and analyzed by two-way 
analysis-of-variance and post hoc tests applying the Bonferroni correction for multiple 
comparisons.  *=p<0.05, **=p<0.01, ***=p<0.001 and ****= p<0.0001 compared to the indicated 
group. 
Figure 4. Depletion of Tregs by treatment of DEREG mice with diphtheria toxin (DT) prevents 
the bone anabolic activity of iPTH. A,B.  Relative and absolute frequency of BM Tregs. C. 
Wnt10b mRNA levels in BM CD8+ T cells. D. Images of representative 3-dimensional µCT 
reconstructions of examined femurs from each group. E. Femoral trabecular bone volume 
(BV/TV) as measured by µCT scanning. F. Femoral cortical bone volume (Ct.Vo) by µCT 
scanning.  G. Images are representative sections displaying the calcein double-fluorescence 
labeling. Original magnification x 20. H. Mineral apposition rate (MAR). I. Bone formation rate 
(BFR). J The number of osteoblasts per mm bone surface (N.Ob/BS). K. The percentage of 
bone surface covered by osteoblasts (Ob.S/BS). L. The images show tartrate resistant acid 
phosphatase (TRAP) stained sections of the distal femur. Original magnification x 40. M. The 
number of osteoclasts per mm bone surface (N.Oc/BS). N. The percentage of bone surface 
covered by osteoclasts (Oc.S/BS). O. Serum levels of osteocalcin, a marker of bone formation. 
P. Serum levels of type 1 cross-linked C-telopeptide (CTX), a marker of resorption. n=9-13 mice 
per group. Data are expressed as Mean + SEM.  All data were normally distributed according to 
the Shapiro-Wilk normality test and analyzed by two-way analysis-of-variance and post hoc 
tests applying the Bonferroni correction for multiple comparisons. *=p<0.05, **=p<0.01, 
***=p<0.001 and ****= p<0.0001 compared to the indicated group. 
Figure 5. iPTH increases Wnt10b transcription by promoting the binding of NFAT/SMAD 
complexes to the Wnt10b promoter. A.  Expression of Wnt10b mRNA by sorted BM 
conventional CD4+ cells (TCRb+CD4+eGFP- cells), Tregs (TCRb+CD4+ eGFP + cells) and 
CD8+ T cells from B6.Foxp3.eGFP reporter mice treated with vehicle or iPTH for 4 weeks. B. 
The NFAT activator ionomycin and TGFb stimulate Wnt10b mRNA expression in splenic CD8+ 
T cells. C. ChIP assays demonstrating that in vivo iPTH treatment increases the binding of 
NFAT1, NFAT2 and SMAD3, but not of SMAD2, to the Wnt10b promoter in BM CD8+ T cells. 
Cells from 4-5 mice were pooled to generate 1 sample. D.  Diagrammatic representation of the 
Wnt10b promoter and effects of promoter deletion on the activity of Wnt10b-luciferase reporter 
constructs in primary splenic CD8+ T cells and EL4 T cells. Cells were stimulated with 
Ionomycin (500 ng/ml) and TGFb (5 ng/ml) for 24 hours to induce reporter activity. n= 3 samples 
per group. E. Effects of mutation of the SMAD and NFAT binding sites on the Wnt10b promoter 
on the activity of a luciferase-Wnt10b reporter constructs in primary splenic CD8+ T cells and 
EL4 cells. Cells were stimulated with Ionomycin (500 ng/ml) and TGFb (5 ng/ml) for 24 hours to 
induce reporter activity. Data are expressed as Mean + SEM. Data were analyzed by Kruskal-
Wallis and Dunn’s multiple comparisons non-parametric tests, as they were not normally 
distributed as assessed by Shapiro-Wilk normality test.  Panel A: n = 5 per group, ****= 
p<0.0001 compared the corresponding vehicle group; Panel B: n = 3 per group, * = p <0.05, and 
****= p<0.0001 compared the corresponding time 0. Panels C-E: n= 3 samples per group, , **= 
p<0.01, ***= p<0.001 and ****= p<0.0001 compared to Veh Irr.Ab or empty vector. 
Figure 6. Effects of PTH and Tregs on NFAT1/2 and SMAD2/3 activation in CD8+ T cells. A. 
Western blotting analysis of NFAT1, NFAT2, pSMAD2, and pSMAD3 in BM CD8+ T cells. The 
figure shows one representative experiment of 3 experiments. B,C. Relative and absolute 
frequency of BM LAP+ Tregs. D. TGFb1 protein levels in purified BM CD4+ T cells culture 
media. E. mRNA levels of TGFb1 in BM Tregs. F. TGFb1 mRNA expression by purified BM 
cells populations. G. Western blotting analysis of NFAT1, NFAT2, pSMAD2, pSMAD3, c-Jun 
and c-Fos in purified splenic CD8+ T cells. CD8+ T cells were unstimulated, activated with OVA 
peptide pulsed DCs with and without induced Tregs for 2h. The figure shows one representative 
experiment of 3 experiments. H. Western blotting analysis of c-Fos and c-Jun in BM CD8+ T 
cells. The figure shows one representative experiment of 3 experiments. R.I.= Relative Intensity. 
I. Coculture with induced Tregs increases the baseline and the PTH-induced expression of 
Wnt10b by CD8+ T cells in an APC assay. J. Western blotting analysis of NFAT1, NFAT2, 
pSMAD2, pSMAD3, c-Jun and c-Fos in purified splenic CD8+ T cells stimulated with PTH (100 
nM for 30 min). CD8+ T cells were unstimulated, activated with OVA peptide pulsed DCs with 
and without CD28 signaling blocking by CTLA-4-Ig treatment. The figure shows one 
representative experiment of 3 experiments. In panels A,F,G,I, Laminin B1 was used as nuclear 
loading control. Tubulin was used as cytoplasmic loading control.  K. Blockade of CD28 
signaling by CTLA-4-Ig increases the baseline and the PTH-induced expression of Wnt10b by 
CD8+ T cells in an APC assay. L. Activation of TCR signaling in the absence of CD28 signaling 
stimulates Wnt10b gene expression in primary splenic CD8+ T cells. The NFAT inhibitor 11R 
VIVIT blocks Wnt10b gene expression in the absence of CD28 stimulation. Panels B-F and I,K: 
n = 5-8 mice per group. Data are expressed as mean + SEM. Panels B-F and I,K: Data were 
analyzed by unpaired t-tests or two-way analysis-of-variance and post hoc tests applying the 
Bonferroni correction for multiple comparisons. Panel L: Data were analyzed by Kruskal-Wallis 
non-parametric test as they were not normally distributed as assessed by Shapiro-Wilk 
normality test. * = p <0.05, **= p<0.01, ***= p<0.001 and ****= p<0.0001 compared to vehicle or 
the indicated group.  
Figure 7. Effects of iPTH treatment on CD28 signaling in BM T cells and the expression of 
CD80 and CD86 on BM mature dendritic cells (DCs). A. Western blotting analysis of Phospho-
PI3K p85 in BM CD8+ T cells.  The figure shows one representative experiment of 5 total 
experiments. R.I.= Relative Intensity.  B. % of pAKT+ BM CD8+ T cells.  C. pAKT levels in BM 
C8+ T cells. D. Relative frequency of BM CD80+ mature DCs. E. Absolute frequency of BM 
CD80+ mature DCs. F. Relative frequency of BM CD86+ mature DCs.  G. Absolute frequency of 
BM CD86+ mature DCs. Panels B,C: n = 5-8 mice per group. Panels D-G: n = 12 mice per 
group. Data are expressed as mean + SEM. Data were analyzed by unpaired t-tests or two-way 
analysis-of-variance and post hoc tests applying the Bonferroni correction for multiple 
comparisons. **= p<0.01, ***= p<0.001 and ****= p<0.0001 compared to vehicle or the indicated 
group.  
Figure 8. Diagrammatic representation of the mechanism by which iPTH treatment stimulates 
bone formation and increases bone mass. iPTH increases the differentiation of naïve CD4+ T 
cells into Tregs and expands the pool of BM Tregs by up-regulating the production of IGF-1 and 
TGFb in BM microenvironment and by increasing the sensitivity of conventional CD4+ T cells to 
TGFb. mature Tregs do not express PPR and are not directly targeted by iPTH. Membrane-
bound TGFb produced by Tregs activates SMAD signaling in CD8+ T cells while iPTH activates 
NFAT signaling in CD8+ T cells. Moreover, Tregs downregulate CD28 signaling in CD8+ T cells, 
lowering the activation of AP-1, thus preventing the association of NFAT and AP-1.  In such 
conditions of low AP-1 levels, NFAT bind together with SMAD to the Wnt10 promoter activating 
Wnt10b transcription.  Direct stimulation of CD8+ T cells by iPTH further upregulate Wnt10b 
gene expression. Wnt10b is known to activate Wnt signaling in mesenchymal stem cells and 
their osteogenic progeny, leading to increased osteoblast proliferation and differentiation and 
lower osteoblast apoptosis.  This increase in osteoblastogenesis and osteoblast life span 
increases bone formation and bone trabecular bone volume. 
  
  
Figure 1. Teriparatide treatment in humans increases the absolute and relative number of 
Tregs in peripheral blood and TGFb expression by Tregs. A.  Relative frequency of Tregs in 
PBMC at 3 and 6 months of treatment. n = 17 patients per group. B. Absolute frequency of 
Tregs in PBMC at 3 and 6 months of treatment.  n = 20 patients per group. C. mRNA levels of 
TGFb1 in peripheral blood CD4+CD25+ T cells at 3 and 6 months of treatment.  n = 9 patients 
per group. D. Relative frequency of Tregs in cultures of in peripheral blood CD4+CD25+ T cells 
stimulated with vehicle or PTH. E. mRNA levels of TGFb1 in peripheral blood CD4+CD25+ T 
cells stimulated with vehicle or PTH. All data are expressed as Mean + SEM. All data were 
normally distributed according to the Shapiro-Wilk normality test and analyzed by 2-way 
ANOVA for repeated measures. *= p<0.05, **= p<0.01, and ***= p<0.001 compared to 
baseline. # = p<0.05, and ## = p<0.01, compared to Ca + D group. 
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Figure 2. iPTH treatment increases the number of BM Tregs and Treg differentiation. To 
determine the effect of treatment on the number of Tregs, BM TCRb+CD4+Foxp3+ T cells 
were counted by flow cytometry following 1, 2 and 4 weeks of treatment with vehicle or iPTH.  
To assess Treg differentiation, conventional CD4+ T cells (TCRb+CD4+eGFP-) from 
B6.Foxp3.eGFP reporter mice were transferred into TCRb-/-mice. Recipient mice were treated 
with vehicle or iPTH for 1,2 or 4 weeks starting 2 weeks after the T cell transfer. The number of 
BM TCRb+CD4+eGFP+ cells was then determined by flow cytometry.  A.  Relative frequency 
of BM Tregs at 1, 2 and 4 weeks of treatment. n = 10-32 mice per group. B. Absolute 
frequency of Tregs at 1, 2, and 4 weeks of treatment.  n = 10-32 mice per group. C.  Relative 
frequency of eGFP+ Tregs at 1, 2, and 4 weeks of treatment n = 10 mice per group. D. 
Absolute frequency of eGFP+ Tregs at 1, 2, and 4 weeks of treatment n = 10 mice per group. 
Data are expressed as Mean + SEM. All data were normally distributed according to the 
Shapiro-Wilk normality test and analyzed by unpaired T tests. ***= p<0.001, and ****= 
p<0.0001 compared to the corresponding vehicle. 
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Figure 3. Depletion of Tregs by treatment with anti-CD25 Ab prevents the bone anabolic activity of iPTH. A,B. 
Relative and absolute frequency of BM Tregs. C. Wnt10b mRNA levels in BM CD8+ T cells. D. Images of 
representative 3-dimensional µCT reconstructions of examined femurs from each group E. Femoral trabecular 
bone volume (BV/TV) as measured by µCT scanning. F. Femoral cortical bone volume (Ct.Vo) by µCT scanning G. 
Images are representative sections displaying the calcein double-fluorescence labeling. Original magnification x 20. 
H. Mineral apposition rate (MAR), I. Bone formation rate per mm bone surface (BFR/BS). J. The number of 
osteoblasts per mm bone surface (N.Ob/BS). K. The percentage of bone surface covered by osteoblasts 
(Ob.S/BS).  L. The images show tartrate resistant acid phosphatase (TRAP) stained sections of the distal femur.  
Original magnification x 40. M. The number of osteoclasts per mm bone surface (N.Oc/BS).  N. The percentage of 
bone surface covered by osteoclasts (Oc.S/BS). O. Serum levels of osteocalcin (OCN), a marker of bone 
formation. P. Serum levels of type 1 cross-linked C-telopeptide (CTX), a marker of resorption. n=10-25 mice per 
group.  Data are expressed as Mean + SEM. All data were normally distributed according to the Shapiro-Wilk 
normality test and analyzed by two-way analysis-of-variance and post hoc tests applying the Bonferroni correction 
for multiple comparisons.  *=p<0.05, **=p<0.01, ***=p<0.001 and ****= p<0.0001 compared to the indicated group. 
  
Figure 4. Depletion of Tregs by treatment of DEREG mice with diphtheria toxin (DT) prevents the bone anabolic 
activity of iPTH. A,B.  Relative and absolute frequency of BM Tregs. C. Wnt10b mRNA levels in BM CD8+ T cells. 
D. Images of representative 3-dimensional µCT reconstructions of examined femurs from each group. E. Femoral 
trabecular bone volume (BV/TV) as measured by µCT scanning. F. Femoral cortical bone volume (Ct.Vo) by µCT 
scanning.  G. Images are representative sections displaying the calcein double-fluorescence labeling. Original 
magnification x 20. H. Mineral apposition rate (MAR). I. Bone formation rate (BFR). J The number of osteoblasts 
per mm bone surface (N.Ob/BS). K. The percentage of bone surface covered by osteoblasts (Ob.S/BS). L. The 
images show tartrate resistant acid phosphatase (TRAP) stained sections of the distal femur. Original magnification 
x 40. M. The number of osteoclasts per mm bone surface (N.Oc/BS). N. The percentage of bone surface covered 
by osteoclasts (Oc.S/BS). O. Serum levels of osteocalcin, a marker of bone formation. P. Serum levels of type 1 
cross-linked C-telopeptide (CTX), a marker of resorption. n=9-13 mice per group. Data are expressed as Mean + 
SEM.  All data were normally distributed according to the Shapiro-Wilk normality test and analyzed by two-way 
analysis-of-variance and post hoc tests applying the Bonferroni correction for multiple comparisons. *=p<0.05, 
**=p<0.01, ***=p<0.001 and ****= p<0.0001 compared to the indicated group. 
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Figure 5. iPTH increases Wnt10b transcription by promoting the binding of NFAT/SMAD complexes to the Wnt10b 
promoter. A.  Expression of Wnt10b mRNA by sorted BM conventional CD4+ cells (TCRb+CD4+eGFP- cells), 
Tregs (TCRb+CD4+ eGFP + cells) and CD8+ T cells from B6.Foxp3.eGFP reporter mice treated with vehicle or 
iPTH for 4 weeks. B. The NFAT activator ionomycin and TGFb stimulate Wnt10b mRNA expression in splenic 
CD8+ T cells. C. ChIP assays demonstrating that in vivo iPTH treatment increases the binding of NFAT1, NFAT2 
and SMAD3, but not of SMAD2, to the Wnt10b promoter in BM CD8+ T cells. Cells from 4-5 mice were pooled to 
generate 1 sample. D.  Diagrammatic representation of the Wnt10b promoter and effects of promoter deletion on 
the activity of Wnt10b-luciferase reporter constructs in primary splenic CD8+ T cells and EL4 T cells. Cells were 
stimulated with Ionomycin (500 ng/ml) and TGFb (5 ng/ml) for 24 hours to induce reporter activity. n= 3 samples 
per group. E. Effects of mutation of the SMAD and NFAT binding sites on the Wnt10b promoter on the activity of a 
luciferase-Wnt10b reporter constructs in primary splenic CD8+ T cells and EL4 cells. Cells were stimulated with 
Ionomycin (500 ng/ml) and TGFb (5 ng/ml) for 24 hours to induce reporter activity. Data are expressed as Mean + 
SEM. Data were analyzed by Kruskal-Wallis and Dunn’s multiple comparisons non-parametric tests, as they were 
not normally distributed as assessed by Shapiro-Wilk normality test.  Panel A: n = 5 per group, ****= p<0.0001 
compared the corresponding vehicle group; Panel B: n = 3 per group, * = p <0.05, and ****= p<0.0001 compared 
the corresponding time 0. Panels C-E: n= 3 samples per group, , **= p<0.01, ***= p<0.001 and ****= p<0.0001 
compared to Veh Irr.Ab or empty vector. 
 
  
Figure 6. Effects of PTH and Tregs on NFAT1/2 and SMAD2/3 activation in CD8+ T cells. A. Western blotting 
analysis of NFAT1, NFAT2, pSMAD2, and pSMAD3 in BM CD8+ T cells. The figure shows one representative 
experiment of 3 experiments. B,C. Relative and absolute frequency of BM LAP+ Tregs. D. TGFb1 protein levels in 
purified BM CD4+ T cells culture media. E. mRNA levels of TGFb1 in BM Tregs. F. TGFb1 mRNA expression by 
purified BM cells populations. G. Western blotting analysis of NFAT1, NFAT2, pSMAD2, pSMAD3, c-Jun and c-Fos 
in purified splenic CD8+ T cells. CD8+ T cells were unstimulated, activated with OVA peptide pulsed DCs with and 
without induced Tregs for 2h. The figure shows one representative experiment of 3 experiments. H. Western 
blotting analysis of c-Fos and c-Jun in BM CD8+ T cells. The figure shows one representative experiment of 3 
experiments. R.I.= Relative Intensity. I. Coculture with induced Tregs increases the baseline and the PTH-induced 
expression of Wnt10b by CD8+ T cells in an APC assay. J. Western blotting analysis of NFAT1, NFAT2, pSMAD2, 
pSMAD3, c-Jun and c-Fos in purified splenic CD8+ T cells stimulated with PTH (100 nM for 30 min). CD8+ T cells 
were unstimulated, activated with OVA peptide pulsed DCs with and without CD28 signaling blocking by CTLA-4-Ig 
treatment. The figure shows one representative experiment of 3 experiments. In panels A,F,G,I, Laminin B1 was 
used as nuclear loading control. Tubulin was used as cytoplasmic loading control.  K. Blockade of CD28 signaling 
by CTLA-4-Ig increases the baseline and the PTH-induced expression of Wnt10b by CD8+ T cells in an APC 
assay. L. Activation of TCR signaling in the absence of CD28 signaling stimulates Wnt10b gene expression in 
primary splenic CD8+ T cells. The NFAT inhibitor 11R VIVIT blocks Wnt10b gene expression in the absence of 
CD28 stimulation. Panels B-F and I,K: n = 5-8 mice per group. Data are expressed as mean + SEM. Panels B-F 
and I,K: Data were analyzed by unpaired t-tests or two-way analysis-of-variance and post hoc tests applying the 
Bonferroni correction for multiple comparisons. Panel L: Data were analyzed by Kruskal-Wallis non-parametric test 
as they were not normally distributed as assessed by Shapiro-Wilk normality test. * = p <0.05, **= p<0.01, ***= 
p<0.001 and ****= p<0.0001 compared to vehicle or the indicated group.  
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Figure 7. Effects of iPTH treatment on CD28 signaling in BM T cells and the expression of CD80 and CD86 on BM 
mature dendritic cells (DCs). A. Western blotting analysis of Phospho-PI3K p85 in BM CD8+ T cells.  The figure 
shows one representative experiment of 5 total experiments. R.I.= Relative Intensity.  B. % of pAKT+ BM CD8+ T 
cells.  C. pAKT levels in BM C8+ T cells. D. Relative frequency of BM CD80+ mature DCs. E. Absolute frequency 
of BM CD80+ mature DCs. F. Relative frequency of BM CD86+ mature DCs.  G. Absolute frequency of BM CD86+ 
mature DCs. Panels B,C: n = 5-8 mice per group. Panels D-G: n = 12 mice per group. Data are expressed as mean 
+ SEM. Data were analyzed by unpaired t-tests or two-way analysis-of-variance and post hoc tests applying the 
Bonferroni correction for multiple comparisons. **= p<0.01, ***= p<0.001 and ****= p<0.0001 compared to vehicle 
or the indicated group.  
 
 
  
Figure 8. Diagrammatic representation of the mechanism by which iPTH treatment stimulates bone formation and 
increases bone mass. iPTH increases the differentiation of naïve CD4+ T cells into Tregs and expands the pool of 
BM Tregs by up-regulating the production of IGF-1 and TGFb in BM microenvironment and by increasing the 
sensitivity of conventional CD4+ T cells to TGFb. mature Tregs do not express PPR and are not directly targeted by 
iPTH. Membrane-bound TGFb produced by Tregs activates SMAD signaling in CD8+ T cells while iPTH activates 
NFAT signaling in CD8+ T cells. Moreover, Tregs downregulate CD28 signaling in CD8+ T cells, lowering the 
activation of AP-1, thus preventing the association of NFAT and AP-1.  In such conditions of low AP-1 levels, NFAT 
bind together with SMAD to the Wnt10 promoter activating Wnt10b transcription.  Direct stimulation of CD8+ T cells 
by iPTH further upregulate Wnt10b gene expression. Wnt10b is known to activate Wnt signaling in mesenchymal 
stem cells and their osteogenic progeny, leading to increased osteoblast proliferation and differentiation and lower 
osteoblast apoptosis.  This increase in osteoblastogenesis and osteoblast life span increases bone formation and 
bone trabecular bone volume. 
 
 
